

Review

Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg

Mepur H. Ravindranath ^{1,2,*}, Fatiha El Hilali ³  and Edward J. Filippone ⁴¹ Department of Hematology and Oncology, Children's Hospital, Los Angeles, CA 90027, USA² Emeritus Research Scientist at Terasaki Foundation Laboratory, Santa Monica, CA 90064, USA³ Mohamed V. Hospital, Mekines 50060, Morocco; hfatiha@gmail.com⁴ Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19145, USA; kidneys@comcast.net

* Correspondence: thiruranganath04@gmail.com

Abstract: HLA class-I (HLA-I) polyreactive monoclonal antibodies (mAbs) reacting to all HLA-I alleles were developed by immunizing mice with HLA-E monomeric, α -heavy chain (α HC) open conformers (OCs). Two mAbs (TFL-006 and TFL-007) were bound to the α HC's coated on a solid matrix. The binding was inhibited by the peptide ¹¹⁷AYDGKDY¹²³, present in all alleles of the six HLA-I isoforms but masked by β 2-microglobulin (β 2-m) in intact HLA-I trimers (closed conformers, CCs). IVIg preparations administered to lower anti-HLA Abs in pre- and post-transplant patients have also shown HLA-I polyreactivity. We hypothesized that the mAbs that mimic IVIg HLA-I polyreactivity might also possess the immunomodulatory capabilities of IVIg. We tested the relative binding affinities of the mAbs and IVIg for both OCs and CCs and compared their effects on (a) the phytohemagglutinin (PHA)-activation T-cells; (b) the production of anti-HLA-II antibody (Ab) by B-memory cells and anti-HLA-I Ab by immortalized B-cells; and (c) the upregulation of CD4+, CD25+, and Fox P³+ T-regs. The mAbs bound only to OC, whereas IVIg bound to both CC and OC. The mAbs suppressed blastogenesis and proliferation of PHA-activated T-cells and anti-HLA Ab production by B-cells and expanded T-regs better than IVIg. We conclude that a humanized version of the TFL-mAbs could be an ideal, therapeutic IVIg-mimetic.

Keywords: intravenous immunoglobulin (IVIg); human leukocyte antigen-I (HLA-1); polyreactive mAbs; monospecific mAbs; shared epitopes; immunosuppression; T-cells; B-memory cells; T-regulatory cells; blastogenesis; proliferation; antibody production



Citation: Ravindranath, M.H.; Hilali, F.E.; Filippone, E.J. Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg. *Vaccines* **2021**, *9*, 680. <https://doi.org/10.3390/vaccines9060680>

Academic Editor: Tatsuya Yamazaki

Received: 28 April 2021

Accepted: 5 June 2021

Published: 21 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Personalized, passive immunotherapy encompasses the transfer of monoclonal antibodies (mAbs), polyclonal antibodies (Abs), and purified natural Abs for the specific purpose of either upregulating or suppressing immune functions, depending on the nature and status of the underlying disease. A variety of mAbs, capable of performing specific functions, are available. These include antibodies capable of depleting various cell types such as B-cells (rituximab), CD52-bearing leukocytes (alemtuzumab), and CD33-bearing cells (gemtuzumab). Additionally, mAbs can inhibit various cytokine pathways such as the TNF–TNFR axis (etanercept, adalimumab, infliximab) and the IL-6-IL-6R axis (tocilizumab, actemra). In contrast, therapeutic intravenous immunoglobulin (IVIg) contains purified natural Abs, prepared by pooling and purifying IgG from the plasma of 10 to 60 thousand normal and healthy donors. The United States Food and Drug Administration (FDA) has approved immunoprophylaxis with IVIg therapy for chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), primary immunodeficiency (PI), secondary immunodeficiency in chronic lymphocytic leukemia, pediatric

human immunodeficiency virus (HIV) infection, Kawasaki disease, prevention of graft vs. host disease in adult bone marrow transplant recipients, and organ transplantation [1].

The presence of pre-existing Abs in a potential organ transplant recipient is referred to as sensitization. It remains one of the significant immunological barriers to receiving an organ. As well as restricting the availability of a given organ for a particular patient, these antibodies cause long-term graft attrition when present post-transplantation [2,3]. IVIg is administered to end-stage organ disease patients pre-transplantation and allograft recipients post-transplantation for reduction (desensitization) of these HLA Abs. The exact mechanism of desensitization by IVIg has not been elucidated. However, IVIg *per se* contains polyreactive, natural IgGs against multiple targets, including endogenous and exogenous Abs, immunomodulating peptides, blood group antigens, and various cytokines. Whereas some of the immunoregulatory mechanisms of the action of IVIg have been proven *in vitro* and animal models, many proposed mechanisms remain enigmatic due to IVIg polyantigen reactivity, polyclonality, and diversity in the preparations of IVIg. Several mechanisms of action of IVIg have been proposed [4]. These include (a) Fc-receptor blockade, (b) neutralization of Abs by idiotypic and anti-idiotypic Abs, (c) blockade of the Fas apoptotic pathway by anti-Fas auto-Abs, (d) regulation of complement components, (e) modulation of cytokine secretion, (f) hindrance of natural-killer cell activity, (g) inhibition of matrix metalloproteinase-9, (h) suppression of NF- κ B activation and I κ B degradation, (i) G1 cell cycle arrest, (j) prevention of tumor growth, (k) decrease in leukocyte recruitment, (l) attenuation of T-cell stimulation, (m) effects on Ab kinetics, and (n) effects on dendritic cells. These mechanisms of IVIg are not mutually exclusive and operate synergistically.

Additionally, more observations have accrued to document that normal, healthy human sera contain a diverse variety of IgG Abs against allo-HLA molecules [5–9]. Therefore, the IVIg purified from the pooled plasma of thousands of healthy individuals clearly carries allo-HLA Abs.

Our research commenced with studying the structure of a non-classical HLA class-I (HLA-I) antigen, namely HLA-E and anti-HLA-E mAbs [10,11]. Anti-HLA antibodies do not react with an entire antigen; like all antibodies, the reaction is against a portion of the antigen termed an epitope. At the center of the epitope is an eplet consisting of one to several amino acids recognized by the complementarity-determining regions of the antibody. Epitopes may be specific to a single HLA locus or HLA allele (private epitopes, *vide infra*). Other times, the epitope may be shared by other loci or alleles (public epitopes, *vide infra*). The unique and shared amino acid sequences of the diverse HLA-I antigens were identified to elucidate whether the mAbs generated by immunizing an HLA-I antigen recognized public or private epitopes. In addition, the relative immunoregulatory capability of antibodies against either public or private epitopes deserves consideration. The objective of this review is to compare the nature and functional characteristics of the polyreactive anti-HLA-E mAbs (TFL-006 and TFL-007) with those of the commercial preparations of therapeutic IVIg as follows:

- Determine if HLA-E shares antigenic amino acid sequences (epitopes) common to all other HLA-I isoforms;
- Document HLA-I polyreactivity of HLA-E mAbs;
- Document HLA-I polyreactivity of the therapeutic preparations of IVIg;
- Compare immunomodulation by IVIg with polyreactive mAbs
 - Suppression of T-cell proliferation;
 - Suppression of antibody production by B cells;
 - Expansion of Foxp³+ Tregs.

2. HLA-E Shares Antigenic Amino Acid Sequences (Epitopes) Common to All Other HLA-I Isoforms

HLA antigens, located on the surface of all nucleated cells of the human body, are of two different major classes, HLA-I and HLA class-II (HLA-II). The genes that encode HLA-I and HLA-II are closely associated with each other on the short arm of human chromosome 6. The entire complex of HLA encompasses four million base pairs of DNA and “is of a size comparable to the genome of *Escherichia coli*” [12].

The HLA-I molecule is a heterodimer with a 45 kDa α -heavy chain (α HC) anchored to the bilayer lipid membrane. It is complexed with a water-soluble, 12 kDa light chain called β 2microglobulin (β 2m) (Figure 1), encoded by a gene located on chromosome 15. The HLA-I loci consist of the classical HLA-Ia and non-classical HLA-Ib loci, each containing three loci: HLA-Ia (HLA-A, HLA-B, and HLA-C) and HLA-Ib (HLA-E, HLA-F, and HLA-G). The α HC of HLA-I consists of different domains encoded by different exons. The leader peptide is encoded by exon 1, and the three extracellular domains (α 1, α 2, and α 3) are encoded by exons 2, 3, and 4 respectively. The transmembrane domain is encoded by exon 5, and the cytoplasmic tail by exons 6 and 7. The antigenic polymorphism of different isoforms is reflected in the amino acid sequences. As noted above, the sequences or epitopes characteristic of each allele of each locus are referred to as its “private epitopes” or “specific sequences.” However, all isoforms also share several common or shared sequences with other alleles of the same locus or other loci, referred to as “public epitopes”.

2.1. Private and Public Epitopes of HLA-E

Table 1 shows both HLA-E amino acid sequences that are specific and those that are shared with alleles of other loci of HLA-I. Some amino acid sequences or epitopes are specific to the HLA-E locus because they are not found in other HLA-Ia or Ib loci. The most striking private epitopes or sequences are ⁶⁵RSARDTA⁷⁰ and ¹⁴³SEGKSNDASE¹⁵². Table 2 summarizes the results of comparing HLA-E sequences with hundreds of alleles from the HLA-Ia and HLA-Ib loci. Some sequences of HLA-E are found in only one allele. The HLA-E sequences, or PRAPWMEQE, and EPPKTHVT are found in HLA-A*3306 and HLA-B*8201, respectively, whereas HLA-E sequences ¹¹⁷AYDGKDY¹²³ and ¹²⁶LNEDLRSWTA¹³⁵ are shared with all other HLA loci (HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G) that we have examined. These latter sequences perfectly befit the definition of “shared” or “public epitopes.”

Table 1. Amino acid sequences of HLA-E compared with HLA-F and HLA-G. There are several sequences restricted to HLA-E, as illustrated by a short sequence, ⁶⁶SARDT⁷⁰, and a long sequence, ¹⁴³SEGKSNDA¹⁵². HLA-E shares several sequences with HLA-F and HLA-G. In addition, HLA-E may selectively share several sequences with HLA-G and a few sequences (¹⁷⁵GKETL¹⁷⁹ and ¹⁹³PISDH¹⁹⁷) with HLA-F. Above all, HLA-E shares ¹¹⁷AYDGKDY¹²³ and ¹²⁶LNEDLRSWTA¹³⁵ with all other HLA isoforms (HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G).

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50
HLA-E	G	S	H	S	L	K	Y	F	H	T	S	V	S	R	P	G	R	G	E	P	R	F	I	S	V	G	Y	V	D	D	T	Q	F	V	R	F	D	N	D	A	A	S	P	R	M	V	P	R	A	P
HLA-G	G	S	H	S	M	R	Y	F	S	A	A	V	S	R	P	G	R	G	E	P	R	F	I	A	M	G	Y	V	D	D	T	Q	F	V	R	F	D	S	D	S	A	C	P	R	M	E	P	R	A	P
HLA-F	G	S	H	S	L	R	Y	F	S	T	A	V	S	R	P	G	R	G	E	P	R	Y	I	A	V	E	Y	V	D	D	T	Q	F	L	R	F	D	S	D	A	A	I	P	R	M	E	P	R	E	P
	a1																				a1																													
	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
HLA-E	W	M	E	Q	E	G	S	E	Y	W	D	R	E	T	R	S	A	R	D	T	A	Q	L	F	R	V	N	L	R	T	L	R	G	Y	Y	N	Q	S	E	A	G	S	H	T	L	Q	W	M	H	G
HLA-G	W	V	E	Q	E	G	P	E	Y	W	E	E	E	T	R	N	T	K	A	H	A	Q	T	D	R	M	N	L	Q	T	L	R	G	Y	Y	N	Q	S	E	A	S	S	H	T	L	Q	W	M	I	G
HLA-F	W	V	E	Q	E	G	P	Q	Y	W	E	W	T	T	G	Y	A	K	A	N	A	Q	T	D	R	V	A	L	R	N	L	L	R	R	Y	N	Q	S	E	A	G	S	H	T	L	Q	G	M	N	G
	a2																				a2																													
	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150
HLA-E	C	E	L	G	P	D	R	R	F	L	R	G	Y	E	Q	F	A	Y	D	G	K	D	Y	L	T	L	N	E	D	L	R	S	W	T	A	V	D	T	A	A	Q	I	S	E	G	K	S	N	D	A
HLA-G	C	D	L	G	S	D	G	R	L	L	R	G	Y	E	Q	Y	A	Y	D	G	K	D	Y	L	A	L	N	E	D	L	R	S	W	T	A	A	D	T	A	A	Q	I	S	K	R	K	C	E	A	A
HLA-F	C	D	M	G	P	D	G	R	L	L	R	G	Y	H	Q	H	A	Y	D	G	K	D	Y	I	S	L	N	E	D	L	R	S	W	T	A	A	D	T	V	A	Q	I	T	Q	R	F	Y	E	A	E
											SHARED WITH HLA-A/B & -C										SHARED WITH HLA-A, HLA-B & HLA-C																													
	a2																				a2																													
	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200
HLA-E	S	E	A	E	H	Q	R	A	Y	L	E	D	T	C	V	E	W	L	H	K	Y	L	E	K	G	K	E	T	L	L	H	L	E	P	P	K	T	H	V	T	H	H	P	I	S	D	H	E	A	T
HLA-G	N	V	A	E	Q	R	R	A	Y	L	E	G	T	C	V	E	W	L	H	R	Y	L	E	N	G	K	E	M	L	Q	R	A	D	P	P	K	T	H	V	T	H	H	P	V	F	D	Y	E	A	T
HLA-F	E	Y	A	E	E	F	R	T	Y	L	E	G	E	C	L	E	L	L	R	R	Y	L	E	N	G	K	E	T	L	Q	R	A	D	P	P	K	A	H	V	A	H	H	P	I	S	D	H	E	A	T
	a2																				a2																													
	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250
HLA-E	L	R	C	W	A	L	G	F	Y	P	A	E	I	T	L	T	W	Q	Q	D	G	E	G	H	T	Q	D	T	E	L	V	E	T	R	P	A	G	D	G	T	F	Q	K	W	A	A	V	V	V	P
HLA-G	L	R	C	W	A	L	G	F	Y	P	A	E	I	I	L	T	W	Q	R	D	G	E	D	Q	T	Q	D	V	E	L	V	E	T	R	P	A	G	D	G	T	F	Q	K	W	A	A	V	V	V	P
HLA-F	L	R	C	W	A	L	G	F	Y	P	A	E	I	T	L	T	W	Q	R	D	G	E	E	Q	T	Q	D	T	E	L	V	E	T	R	P	A	G	D	G	T	F	Q	K	W	A	A	V	V	V	P

Table 2. Comparison of the amino acid sequence of HLA-E with sequences of five other HLA isoforms. Several peptide sequences of HLA-E are shared with the alleles of other HLA-I isoforms. Note that amino acid sequence AYDGKDY is shared with the maximum number of alleles of all isoforms of HLA-I, while sequences PRAPWMEQE and EPPKTHVT are shared with one allele of HLA-A (A*3306) and one allele of HLA-B (B*8201). The bioinformatics analysis was carried out using the Immune Epitope Database (IEDB) to predict the antigenicity rank of epitopes. The Chou and Fasman beta turn, Kolaskar and Tongaonkar antigenicity, Karplus and Schulz flexibility, and Parker hydrophilicity prediction methods in IEDB were employed. The methods predict the probability of specific sequences in HLA-E that bind to Abs being in a beta turn region, being antigenic, being flexible, or being in a hydrophilic region. Antigenicity rank is calculated by pooling the probability values.

HLA-E Peptide Sequences	HLA Alleles						Method 1	Method 2	Method 3	Method 4	Rank of Antigenicity
Prediction SCORES											
	Classical HLA-Ib			Non-Classical HLA-Ib			Specificity	Beta-Turn	Antigenicity	Flexibility	Hydrophilicity
[total number of amino acids]	A	B	Cw	F	G		Chou & Fasman (1978)	Kolaskar & Tangaonkar (1990)	Karplus & Schulz (1985)	Parker (1986)	
⁴⁷ PRAPWMEQE ⁵⁵ [9]	1	0	0	0	0	A*3306	0.993	0.948	0.969	0.586/1.143/1.657	
⁵⁸ EYWDRETR ⁶⁵ [8]	5	0	0	0	0	A restricted	0.993	0.915	1.024	3.301/2.786	
⁹⁰ AGSHTLQW ⁹⁷ [8]	1	10	48	0	0	Polyspecific	1.019	1.033	0.989	2.629/0.901	
¹⁰⁸ RFLRGYE ¹¹⁴ [7]	24	0	0	0	0	A restricted	0.933	0.996	0.996	0.229	
¹¹⁵ QFAYDGKDY ¹²³ [9]	1	104	75	0	0	Polyspecific	1.059	1.001	0.993	2.629/3.201	
¹¹⁷ AYDGKDY ¹²³ [7]	491	831	271	21	30	Polyspecific	1.204	0.989	1.061	4.243	
¹²⁶ LNEDLRSWTA ¹³⁵ [10]	239	219	261	21	30	Polyspecific	1.046	0.983	1.039	2.443/2.329	
¹³⁷ DTAAQI ¹⁴² [6]	0	824	248	0	30	Polyspecific	0.813	1.065	0.978	1.957	
¹³⁷ DTAAQIS ¹⁴³ [7]	0	52	4	0	30	Polyspecific	0.946	1.012	0.97	3.414	
¹⁵⁷ RAYLED ¹⁶² [6]	0	1	0	0	0	B*8201	0.929	0.996	0.969	2.601	
¹⁶³ TCVEWL ¹⁶⁸ [6]	282	206	200	0	30	Polyspecific	0.841	1.115	0.929	−0.914	
¹⁸³ EPPKTHVT ¹⁹⁰ [8]	0	0	19	0	0	C restricted	1.029	1.044	1.042	3.043	
⁶⁵ RSARDTA ⁷¹ [7]	0	0	0	0	0	E restricted	1.011	0.952	1.038	4.901	
¹⁴³ SEQKSNDAE ¹⁵² [10]	0	0	0	0	0	E restricted	1.231	0.923	1.222	7.071/6.443/6.257/6.514	

Method 1. Predict beta turns in protein secondary structures. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. *Adv Enzymol Relat Areas Mol Biol.* 1978;47:45-148. DOI: 10.1002/9780470122921.ch2. Method 2. A semi-empirical method which made use of the physicochemical properties of amino acid residues and their frequencies of occurrence in experimentally known segmental epitopes was developed to predict antigenic determinants on proteins. Application of this method to a large number of proteins has shown that the method can predict antigenic determinants with about 75% accuracy, which is better than most of the known methods. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. *FEBS Lett.* 1990 Dec 10;276(1-2):172-4. doi: 10.1016/0014-5793(90)80535-q. Method 3. In this method, a flexibility scale, based on the mobility of protein segments on the basis of the known temperature B factors of the α -carbons of 31 proteins of known structure, was constructed. The calculation based on a flexibility scale is similar to classical calculation, except that the center is the first amino acid of the six amino acids' window length, and there are three scales for describing flexibility instead of a single one. Karplus PA, Schulz GE. Prediction of Chain Flexibility in Proteins—A tool for the Selection of Peptide Antigens. *Naturwissenschaften* 1985; 72:212-3. Method 4. In this method, a hydrophilic scale based on peptide retention times during high-performance liquid chromatography (HPLC) on a reversed-phase column was constructed. A window of seven residues was used for analyzing epitope region. The corresponding value of the scale was introduced for each of the seven residues and the arithmetical mean of the seven residue values was assigned to the fourth, (i+3), residue in the segment. Parker JM, Guo D, Hodges RS. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. *Biochemistry.* 1986 Sep 23; 25(19):5425-32.

STRUCTURE OF HLA-E




Figure 1. HLA-E structure shows specific amino acid sequences, private epitopes, shared amino acid sequences, or public epitopes. (A). Private epitopes recognized by the anti-HLA-E monospecific mAb, TFL-033 (B). Public epitopes are recognized by the anti-HLA-E mAbs, TFL-006, and TFL-007. Both private and public epitopes are shown in yellow.

2.2. The Most Widely Shared Public Epitopes Are Cryptic in HLA-I

The HLA-I molecule is a heterodimer because the α -HC is closely associated with $\beta 2m$ (Figure 1). As a consequence, not all sequences of HLA α -HC are exposed. Figure 1A shows that the specific sequences, or the private epitopes, of HLA-E (shown in yellow), $^{65}RSARDT^{70}$ and $^{143}SEGKSNDASE^{152}$, are exposed for direct binding of Abs. Figure 1B shows that the most commonly shared sequences or the public epitopes (shown in yellow) $^{117}AYDGKDY^{123}$ and $^{126}LNEDLRSWTA^{135}$ are cryptic, as they lie in close proximity with $\beta 2m$. Figure 2 illustrates the crypticity of the shared epitope, $^{117}AYDGKDY^{123}$. The exposure of these shared epitopes depends on the nature of the HLA molecule. Most often, the HLA molecules occur as heterodimers, also designated as “closed conformers” or CCs. In CCs, the most prevalent shared epitopes, $^{117}AYDGKDY^{123}$ and $^{126}LNEDLRSWTA^{135}$, are masked by $\beta 2m$. However, in $\beta 2m$ -free α -HCs, designated as “open conformers” (OCs), they are exposed.




Figure 2. Diagrammatic illustration of six isoforms of HLA class I molecules. The upper row shows the structures of intact, trimeric, closed conformers (CCs) of HLA. Note the shortened cytoplasmic tail. The lower row shows monomeric HLA-I (open conformers OCs). OCs of HLA-I expose epitopes masked by $\beta 2m$. These epitopes, particularly $^{117}\text{AYDGKDY}^{123}$ and $^{126}\text{LNEDLRSWTA}^{135}$, are found in almost all alleles of the six isoforms of HLA.

Thus, the HLA-I molecules occur as heterodimers complexed with $\beta 2m$ on the cell surface and as $\beta 2m$ -free α -HC OCs. Schnabl et al. [13] reported that T lymphocytes activated in vitro or in vivo, but not resting, expressed many OCs. Using the mAb W6/32 that specifically recognized HLA-I CCs and the mAbs L45 and HC10 that bound explicitly to OCs but not to CCs, they confirmed the existence of HLA-OCs. Immunoprecipitation and co-capping experiments showed that LA45 was bound to HLA-I OCs at the cell surface. The mAb L45 bound to PHA-activated T-cells from a panel of 12 people with different HLA types, suggesting that LA45 might bind to epitopes shared by all HLA-I α -HCs. The HLA-I OCs expressed on the cell surface of activated T-cells—or EBV-transformed B-cells—are referred to as “peptide-binding empty HLA” [14,15]. The presence of HLA-I OCs was confirmed on activated T-cells in vitro and in vivo and on B cell lines (RAJI, NALM6), EBV-transformed B-cells, and the myeloid cell line KG-1A [16,17]. Interestingly, the expression of OCs on the cell surface in normal human T-cells upon activation and cell division correlated with the level of proliferation [18]. Indeed, the OCs on the cell surface were glycosylated. The inhibition of tyrosine phosphorylation with the Src-family tyrosine kinase inhibitor PP2 resulted in the enhanced release of HLA-I α -HC from the cell surface of activated T-cells. Further studies indicated that the OCs were regulators of ligand–receptor

interactions and had potential implications for immune activation [18–20] and immune regulation [21]. The inflamed tissues in spondyloarthritis showed increased levels of OCs on CD14b+ monocytes compared to other leukocyte subsets. The level of OCs also increased on activated dendritic cells of the extravillous trophoblast [22]. Interestingly, the OCs maintained the peptide-binding groove in vitro [23]. Khare et al. [24] reported that the β 2m-free HCs of HLA-B27 might induce arthritis in transgenic mice, and β 2m-free, HC-specific Abs decreased the disease incidence in this model. OCs exist as dimers or in clusters at the cell surface in vivo [23,25,26], profoundly impacting receptor engagement. Recognition of OCs as ligands by members of the killer Ig receptor family (KIR) and Ig-like transcript (ILT)/LIR/LILR family could influence their immunomodulatory function in inflammatory disease [27]. The shared sequences presented in HLA-E OCs contribute to the generation of HLA-I polyreactivity Abs.

Though the OCs are found on activated immune cells, the soluble forms of HLA-I present in humans also occur as OCs. Demaria et al. [28] found that the levels of OCs in circulation were regulated by proteolytic cleavage. The release was mediated by a Zn^{2+} -dependent, membrane-bound metalloprotease (MMP). Specific separation by the metalloprotease occurs at a site close to the papain cleavage site in the α 3 domain of HLA-I HCs. This site is not accessible to MMP in CCs. During the shedding of HLA-I trimers under different pathological conditions, the exogenous peptide and β 2m dissociate from these CCs, and subsequent cleavage of OCs (Figure 3) may be partially responsible for controlling the levels of OC on the surface of activated cells. Since the shed OCs expose previously cryptic epitopes, they may be recognized by B-cells for antibody production.




Figure 3. Shedding of membrane-bound CC and the shedding results in dissociation of HLA α -HC from β 2m. The membrane-bound α -HC is cleaved by a Zn^{2+} -dependent membrane metalloproteinase. The shed α -HC and β 2m are further degraded. Immune recognition of shed β 2m and α -HC can occur at any time [29,30].

2.3. Antigenicity Rank of the Most Widely Shared Public Epitopes of HLA-E

An Ab directed against a protein antigen can recognize either a linear or a discontinuous sequence (still closely aligned in space due to protein folding) in its native conformation. This so-called eplet is present at the center of an epitope. The immunogenicity of an epitope is defined as its ability to actively induce an immune response. In contrast, the antigenicity of an epitope is defined as its passive ability to be recognized by the immune system. The

antigenicity of a sequence, or epitope, in a polypeptide can be predicted using parameters such as hydrophilicity, flexibility, accessibility, beta turns, cell surface exposure, and polarity. Several methods are known for predicting the antigenicity of a continuous sequence. Chou and Fasman [31] developed a methodology, based on α -turns in protein secondary structures, for predicting antigenicity. Kolaskar and Tongaokar [32] developed a semi-empirical method using the physicochemical properties of amino acid residues and their frequency of occurrence in segmental epitopes. Karplus and Scholtz [33] predicted antigenicity based on three flexibility scales. Parker et al. [34] predicted antigenicity with a novel hydrophilicity scale. In these methods, when computing the score for given residue i , the amino acids in an interval of the chosen length, centered around residue i , are considered.

Further details are provided on the antibody epitope prediction web (http://tools.immuneepitope.org/tools/bcell/iedb_input) (Last updated on 30 May 2021, see also iedb.org for details). The methods were collectively employed to assess the antigenicity ranking of the different sequences of HLA-E listed in Table 2. Among the shared peptide sequences listed in the table, the most prevalent shared epitope, ¹¹⁷AYDGKDY¹²³, ranked first in antigenicity. We have used these peptide sequences and the second-ranking epitope for peptide inhibition studies of anti-HLA-E mAbs and established that mAbs TFL-006 and TFL-007 are the most polyreactive [10,11,35,36].

3. Documentation of HLA-I Polyreactivity of HLA-E mAbs

3.1. Methodology—Development and Characterization of HLA-E mAbs

3.1.1. Anti-HLA-E mAb Production

The mAbs were produced following the recommendations of the National Research Council's Committee on Methods of Producing mAbs [37]. The recombinant α -HCs HLA-E^{R107} and HLA-E^{G107} (source: Immune Monitoring Laboratory, Fred Hutchinson Cancer Research Center, concentration: 10 mg/mL in MES buffer) were used. Two mice were immunized with 50 mg of each antigen in PBS (pH 7.4, 100 mL) admixed with TiterMax (100 mL) (Sigma-Aldrich, St Louis, MO, USA) adjuvant before injection into the footpad and intraperitoneally. Three immunizations were given at about 12-day intervals, with an additional immunization after 12 days for mice receiving HLA-E^{G107}.

The clones were cultured in a medium (RPMI 1640 w/L-glutamine and sodium bicarbonate, with 15% FBS, penicillin, streptomycin, L-glutamine, and sodium pyruvate. Hybridomas were cryopreserved in RPMI containing 10% DMSO and 20% FBS. All culture supernatants were screened for IgG reacting to HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G using single-antigen microbeads on a Luminex platform. The mean fluorescent intensity (MFI) was determined for supernatants after diluting to 1/2. The MFI values were corrected against those obtained with negative control beads. Further details are provided elsewhere [35,38].

3.1.2. HLA-I Antigen-Coated Single Antigen Beads (SABs) and the Luminex Platform for Monitoring the Reactivity and the Density of These mAbs

The affinity of Abs to different HLA-I antigens was monitored on a Luminex Platform, using HLA-I molecules, coated as single antigens, on the multiplex, fluorescinated microbeads. Three different kinds of microbeads were available for investigation, as illustrated in Figure 4: (i) beads with an admixture of CCs and OCs (Regular LABScreen SAB, source: One Lambda, Inc., Canoga Park, CA, USA), (ii) beads restricted to CCs only (iBeads developed by trypsinization of regular LABScreen beads and Immucore LIFECODES SAB), and (iii) beads restricted to OCs (alkali or acid-denatured beads). The regular LABScreen microbeads were coated with HLA-A (31 different antigens), HLA-B (50 different antigens), and HLA-C (16 different antigens). In addition, the HLA-Ia microbeads had built-in control beads: positive beads coated with human IgG and negative beads coated with serum albumin (human or bovine). For HLA-Ib, the control beads (both positive and negative) were added separately.




Figure 4. Three different kinds of microbeads used: Regular beads admixed with CCs and OCs; The acid or alkali treated regular beads with OC only, (iii) beads restricted with CC. The microbeads were characterized using W6/32 (IgG2a) bound to peptide-associated and peptide-free CCs, but not bound to the OCs. HC-10 (IgG2a) recognized CCs devoid of a peptide. HLA-I polyreactive mAb TFL-006 (IgG2a) bound to OCs only and was inhibited by the shared peptides (¹¹⁷AYDGKDY¹²³ and ¹²⁶LNEDLRSWTA¹³⁵) found in all HLA-I isoforms.

The different kinds of microbeads were characterized using three different mAbs (Figure 4). The mAb W6/32 (IgG2a) bound to CCs, but not to OCs [39], and bound to both peptide-associated and peptide-free CCs [40,41]. The mAb HC-10 (IgG2a) recognized an epitope in HLA-I between amino acid positions 57 and 62, with arginine at position 62 (R62) being crucial for HC-10 binding [42]. HC-10 recognized cell surface CCs devoid of a peptide, whereas the presence of a peptide reduced HC-10 reactivity [43]. The mAb TFL-006 (IgG2a) bound to OCs of all HLA-I loci and was inhibited by peptides from the amino acid sequences shared by all HLA-I loci [35,36].

3.2. The HLA Reactivity Groups of mAbs Generated by Recombinant HLA-E OCs

More than 200 hybridomas were generated using the OCs of HLA-E. All mice experiments were carried out under the guidance of Professor Paul I. Terasaki, who owned One Lambda, Inc., in Canoga Park, CA, USA, with animal subject committee approval. The mAbs secreted by these hybridomas were both HLA-E monospecific and HLA-Ia and HLA-Ib polyreactive. These mAbs could be categorized into eight different groups, as shown in Table 3. Group 1 corresponds to monospecific mAbs reacting restrictively with HLA-E. Group 4 refers to HLA-Ib-specific mAbs. Group 10 represents mAbs, recognizing both HLA-Ia and HLA-Ib molecules (Table 4).

Table 3. The HLA-1 signatures of the mAbs generated after immunizing recombinant heavy chains of HLA-E. Group 10 is truly befitting the definition of a polyreactive mAb category.

IMMUNOGEN HLA-E ^{R107} OR HLA-E ^{G107}							
Groups of mAbs	Number of mAbs	HLA-CLASS Ib			HLA-CLASS IC		
		HLA-E	HLA-F	HLA-G	HLA-A	HLA-B	HLA-C
Group 1	24	+	—	—	—	—	—
Group 2	1	+	+	—	—	—	—
Group 3	1	+	—	+	—	—	—
Group 4	8	+	+	+	—	—	—
Group 5	4	+	—	—	—	+	—
Group 6	31	+	—	—	—	+	+
Group 7	109	+	—	—	+	+	+
Group 8	11	+	+	—	+	+	+
Group 9	18	+	—	+	+	+	+
Group 10	7	+	+	+	+	+	+

Table 4. HLA-I allele reactivities of the polyreactive mAbs as compared with monospecific mAbs. The values represent mean fluorescent intensities (MFIs) of the mAbs, corrected against background values. The mAbs were generated using HLA-E-recombinant heavy chains. The number of HLA antigens showing positive reactivity with the mAbs are shown in bold letters.

<i>mAbs</i>	<i>Monospecific</i>	<i>Polyreactive</i>		<i>mAbs</i>	<i>Monospecific</i>	<i>Polyreactive</i>	<i>mAbs</i>	<i>Monospecific</i>	<i>Polyreactive</i>		
	TFL-033 <i>IgG1</i>	TFL-006 <i>IgG2a</i>	TFL-007 <i>IgG2a</i>		TFL-033 <i>IgG1</i>	TFL-006 <i>IgG2a</i>	TFL-007 <i>IgG2a</i>		TFL-033 <i>IgG1</i>	TFL-006 <i>IgG2a</i>	TFL-007 <i>IgG2a</i>
Neg	3	15	7	<i>B* alleles</i>			<i>C* alleles</i>				
Pos	71	88	85	B*0702		1331	841	C*0102		7242	3268
HLA-E	24411	22522	21618	B*0801		2092	1033	C*0202		10690	6084
HLA-F		12650	11035	B*1301		5654	3979	C*0302		5917	3062
HLA-G		7193	2670	B*1302		2237	1426	C*0303		7114	4250
<i>A* alleles</i>				B*1401		11319	8767	C*0304		6584	3891
A*0101		2395	1037	B*1402		4414	2558	C*0401		2843	1272
A*0201		856		B*1501		1097		C*0501		16131	13096
A*0203		1095		B*1502		6256	4497	C*0602		9396	4274
A*0206		1494	843	B*1503		2831	1926	C*0702		12251	6919
A*0301		818		B*1510		2616	1470	C*0801		13456	10733
A*1101		10190	8476	B*1511		9041	5902	C*1203		5055	2102
A*1102		860		B*1512		1624	996	C*1402		8727	4936
A*2301		614		B*1513		5326	3365	C*1502		6030	3225
A*2402		3133	2011	B*1516		5614	3443	C*1601		8462	4364
A*2403		3151	1967	B*1801		6990	4890	C*1701		13521	9069
A*2501		1230	692	B*2705		2591	1576	C*1802		17918	15207
A*2601		3368	1638	B*2708		4437	2671	<i>C* alleles</i>	0	16	16
A*2901		3194	2256	B*3501		10205	8594				
A*2902		2235	1136	B*3701		6472	4338				
A*3001		2229	1237	B*3801		3844	1820				
A*3002		3353	2211	B*3901		7093	5304				
A*3101		858		B*4001		5743	3758				
A*3201		2237	1508	B*4002		6118	4675				
A*3301		2791	1627	B*4006		15643	13758				
A*3303		4212	2961	B*4101		7191	5277				
A*3401		6268	3968	B*4201		636					
A*3402		1399	893	B*4402		7062	4059				
A*3601		5806	3826	B*4403		7256	5638				
A*4301		4420	2364	B*4501		9535	7646				
A*6601		3644	1526	B*4601		6491	4130				
A*6602		1395	789	B*4701		6528	3895				
A*6801		1314	859	B*4801		4365	2716				
A*6802		2078	1276	B*4901							
A*6901		1964	917	B*5001		741					
A*7401		723		B*5101		6205	3724				
A*8001		2841	1430	B*5102		5251	3579				
<i>A* alleles</i>	0	32	24	B*5201		4524	2728				
				B*5301		8807	7323				
				B*5401		5556	4153				
				B*5501		2829	1887				
				B*5601		1386	777				
				B*5701							
				B*5703		1229	600				
				B*5801		10160	8047				
				B*5901		5646	3001				
				B*6701		675					
				B*7301		3347	2171				
				B*7801		6089	4597				
				B*8101		1352	729				
				B*8201		4367	3069				
				<i>B* alleles</i>	0	48	44				

Table 4 compares the HLA-I reactivities of an HLA-E monospecific mAb, TFL-033, with two HLA-I polyreactive mAbs, namely TFL-006 and TFL-007. TFL-006 showed reactivity with 32 alleles of HLA-A, 48 alleles of HLA-B, and 16 alleles of HLA-C, whereas TFL-007 reacted with 24 HLA-A, 44 HLA-B, and 16 HLA-C alleles. TFL-006 did not react with B*4901 and B*5701, although shared sequences (public epitopes) were present. TFL-006 and TFL-007 reacted with all three HLA-Ib isoforms as follows: HLA-E (+++) > HLA-G (++) > HLA-F (+). Among HLA-Ia isoforms, the reactivities in general were as follows: HLA-C (+++) > HLA-B (++) > HLA-A (+). The MFIs of the mAbs against A*1101 were the highest among HLA-A isoforms, with B*4006 the highest among HLA-B isoforms and C*1802 the highest among HLA-C isoforms. Of the seven HLA polyreactive mAbs belonging to group 10, TFL-006 ranked first, and TFL-007 ranked second. The reactivities of other mAbs of group 10 are presented elsewhere [44].

To determine the affinity of the mAbs TFL-006 and TFL-007 for shared sequences in the OCs, synthetic peptides purified by reverse-phase HPLC from GenScript Corporation (Piscataway, NJ, USA) were obtained [10]. Table 2 compares peptide inhibition using three commonly shared peptides, namely DTAAQI, AYDGKDY, and LNE DLRSWTA. These peptides were used, separately, to block the binding of the mAbs to the regular LABScreen SABs, in which the OCs (β 2m-free α -HC) were admixed with intact HLA trimers (CCs). Of the three peptides tested, AYDGKDY blocked more than 52% of the binding to the mAb TFL-006 compared to the other two peptides. Similar results were obtained with mAb TFL-007.

To further ascertain that the mAbs recognized only the OCs, we compared the binding of mAb TFL-006 on LABScreen SABs (One Lambda, Inc., Canoga Park, CA, USA), which contained an admixture of OCs and CCs and with LIFECODES SABs (LSA Class I 03203F beads; Immucor, Norcross, GA, USA) that was devoid of HLA-I OCs [45–48]. The results presented in Table 5 show that the mAb TFL-006 did not bind to any of the alleles of the isoforms of HLA-I on LIFECODES SABs, confirming that mAb TFL-006 recognized only the OCs and did not bind to CCs on the LIFECODES beads. Earlier, we have shown that mAb TFL-006 binds well on acid-denatured LABScreen beads but not on iBeads, in which β 2m-free HCs (OCs) are selectively, enzymatically removed from the regular LABScreen beads [45,46].

Table 5. Evidence showed that HLA-I polyreactive mAb TFL-006 bound to OCs (β 2m-free α HLA HC) but not to CCs (β 2m-associated HLA heavy chains or intact HLA molecules). TFL-006 bound only with LABScreen SABs (contained both open and CCs) but not with LIFECODES, which had only CCs, as established in previous reports [45,47].

		HLA-A		HLA-B	
TFL-006 (20 ug/mL)					
REGULAR LABScreen BEADSET (Lot: LS1A04-lot 10) [Closed Conformers admixed with Open Conformers]					
		90	NC		
		12	PC		
		933	A*01:01		
		339	A*02:01		
		1018	A*02:03		
		193	A*03:01		
		4782	A*11:01		
		537	A*11:02		
		133	A*23:01		
		716	A*24:02		
		2516	A*24:03		
		194	A*25:01		
		2221	A*26:01		
		1017	A*29:01		
		778	A*29:02		
		1496	A*30:01		
		396	A*31:01		
		515	A*32:01		
		1038	A*33:01		
		554	A*33:03		
		1535	A*34:02		
		1353	A*36:01		
		2479	A*43:01		
		1886	A*66:01		
		1454	A*66:02		
		713	A*68:01		
		1185	A*68:02		
		3128	A*69:01		
		652	A*74:01		
		3132	A*80:01		
LIFECODES BEADSET (Lot # 3005619) (Closed Conformers only)					
		0	B*07:02	0	
		0	B*08:01	0	
		12	B*13:02	0	
		0	B*14:01	0	
		3	B*14:02	0	
		0	B*15:01	0	
		0	B*15:02	0	
		0	B*15:03	0	
		0	B*15:12	0	
		0	B*15:13	0	
		0	B*15:16	0	
		0	B*18:01	0	
		0	B*27:05	0	
		0	B*27:08	0	
		0	B*35:01	0	
		0	B*37:01	0	
		0	B*38:01	0	
		0	B*39:01	0	
		0	B*40:01	0	
		0	B*40:02	0	
		0	B*41:01	0	
		0	B*42:01	0	
		0	B*44:02	0	
		0	B*44:03	0	
		0	B*45:01	0	
		0	B*46:01	0	
		0	B*47:01	0	
		10	B*48:01	0	
		0	B*49:01	0	
		0	B*50:01	0	
		8	B*51:01	0	
		0	B*52:01	0	
		2	B*53:01	0	
		0	B*54:01	0	
		0	B*55:01	0	
		0	B*56:01	0	
		0	B*57:01	0	
		0	B*58:01	0	
		1	B*59:01	0	
		0	B*67:01	0	
		2	B*73:01	0	
		0	B*78:01	0	
		0	B*81:01	0	
REGULAR LABScreen BEADSET (Lot: LS1A04-lot 10) [Closed Conformers admixed with Open Conformers]					
		862			
		1226			
		2514			
		7805			
		1831			
		335			
		1935			
		1822			
		770			
		3135			
		3076			
		3096			
		634			
		1659			
		6128			
		2650			
		2521			
		704			
		3429			
		2697			
		3739			
		347			
		3650			
		1829			
		1736			
		3572			
		2152			
		3262			
		1554			
		1799			
		2461			
		2146			
		5442			
		1662			
		2519			
		3662			
		2089			
		5268			
		3553			
		406			
		1423			
		2996			
		1525			

Table 5. Cont.


TFL-006 (20 ug/mL)	
HLA-C	REGULAR LABScreen BEADSET (Lot: LS1A04-lot 10) [Clotted Conformers admixed with Open Conformers]
1 4066 C*01:02	
20 7446 C*02:02	
0 2458 C*03:03	
0 4504 C*03:04	
8 3337 C*04:01	
24 9124 C*05:01	
4 5644 C*06:02	
97 8702 C*07:02	
1 6090 C*08:01	
0 3937 C*14:02	
4 4465 C*15:02	LIFECODES BEADSET (Lot # 3005619) (Closed Conformers only)
0 4648 C*16:01	
10 8296 C*17:01	

4. Documentation of HLA-I Reactivity of the Therapeutic Preparations of IVIg

The FDA, in 2004, approved the Cedars–Sinai IVIg desensitization protocol for minimizing allo-HLA Abs in patients waiting for kidney transplantation, given the known ability of HLA antibodies to destroy an allograft. Removal, or significant reduction, of such Abs, would then allow transplantations to proceed that would have otherwise been contraindicated. Since then, IVIg has emerged as a potential treatment strategy for desensitization protocols, pre-transplantation, and is now used post-transplantation for treating Ab-mediated rejection (AMR) caused by donor-specific anti-HLA Abs (DSA). Several clinical transplant centers adopted this strategy [2,3,49–53]. However, subsequent studies documented that IVIg preparations were often unable to reduce HLA Abs in the sera of transplant patients [54–56]. We examined five different therapeutic preparations of IVIg, namely GamaSTAN S/D (Talecris Biotherapeutics, Inc., Research Triangle Park, NC, USA), Sandoglobulin (6 gr, lot 4305800026; CSL Behring, Kankakee, IL, USA), Octagam (6 gr, lot A913A8431; Octapharma Pharmazeutika, Lachen, Switzerland); IVIGlob EX (VHB Life Sciences Limited, Bangalore, India) [34,35], and Immunoglobulin Normale (IV-LFB-CNTs LFB Biomedicaments, Courtaboeuf Cedex, France)[57].

HLA-I reactivities of the different dilutions (1/2 to 1/128) of IVIg preparations were tested on regular LABScreen SABs, acid-denatured LABScreen SABs (OCs only), and on enzymatically treated regular LABScreen SABs, called iBeads (CCs only). The details of this methodology are presented elsewhere [34]. Figure 5 compares the MFIs, signifying the density of HLA-Ia and HLA-Ib IgG Abs on the three different SABs for IVIg preparations from GamaSTAN (Figure 5A) and octagam (Figure 5B). Table 6 summarizes the HLA-I polyreactivity of commercial preparations of IVIg from different sources. The data presented in Figure 5A,B reveal that the strength of the Abs is much higher in denatured SABs, which is predominant with OCs, than in the CCs restricted to the iBeads. These findings confirmed that the anti-HLA IgG Abs in the IVIg preparations recognized both the CCs and OCs of HLA molecules, but with a higher prevalence of Abs recognizing OCs. To ascertain whether the immunoreactivity of IVIg to HLA-Ia alleles was due to the OCs of HLA-I, the anti-HLA-1a Abs were adsorbed out with Sephadex gel conjugated with OCs of HLA-E and then tested for HLA-E and HLA-Ia reactivity [35]. IVIg immunoreactivity to HLA-Ia was minimized after the adsorbing-out process. Most importantly, HLA-E OCs alone could absorb out a major fraction of anti-HLA-1a antibodies, indicating the prevalence of polyreactive antibodies against HLA-I OCs in IVIg preparations. This unique finding formed the basis for comparing the functional characteristics of IVIg with HLA-I polyreactive mAbs (TFL-006 and TFL-007).


GammaStan IVIG



(A)

Figure 5. Cont.

OctaGram IVIG



(B)

Figure 5. HLA-I polyreactivity of IVIg. IVIg was tested on three kinds of SABs: (i) regular LABScreen bead set coated with an admixture of CCs and OCs, (ii) regular LABScreen bead set treated with a mild acid to convert OCs to CCs. The bead set was loaded with OCs. (iii) “iBeads” generated from regular LABScreen bead sets to enzymatically eliminate OCs, and therefore containing only CCs. The Luminex immunoassay with IVIg from GammaSTAN (A) and Octagam (B) confirmed the HLA-I polyreactivity of IVIg. Importantly, IVIG reacted with the monomeric variants on the acid-denatured SABs better than on iBeads. The density of IgG binding is illustrated by mean fluorescent intensity (MFI), as shown in different colors. The binding affinity of IVIg to monomeric variants was much higher than those recognizing the CC on ‘iBeads.’.

Table 6. HLA-I reactivity of different therapeutic preparations of IVIg.

Therapeutic Preparations of IVIg	Reactivity of Different HLA Class I Antigens					
	Classical HLA-Ia Alleles			Non-Classical HLA-Ib		
	A	B	Cw	E	F	G
IVIg (GamaSTAN, Talecris Biotherapeutics, Inc., Research Triangle Park, NC, USA)	31	50	16	Positive	Positive	Positive
IVIg (Octagam, Octapharma S.A. Argentina Poniente, Mexico, D.F.)	30	47	16	Positive	Positive	Positive
IVIg (Sandoglobulin, CSL Behring, Kankakee, IL, USA)	30	47	16	Positive	Positive	Positive
IVIg (GlobEx, Bangalore, India)	20	39	16	Positive	Positive	Positive
IVIg (IV-LFB-CNTs LFB Biomedicaments, Courtaboeuf Cedex, France)	31	50	16	Positive	Positive	Positive

5. Immunomodulation By IVIg Compared with Polyreactive Monoclonal Antibodies

5.1. Suppression of T-Cell Proliferation: IVIg vs. HLA-I-Polyreactive mAbs

5.1.1. Background and Hypothesis

Activation of T-cells involves both blastogenesis and proliferation. Activation can be accomplished by natural or recombinant cytokines and PHA (phytohemagglutinin). Activation induces transitory expression of several molecules, both within the T-cell or on the cell surface. They include the IL-2 receptor, Fc receptors for IgG, insulin receptors, α fetoprotein, and transferrin receptors, MICA, HLA-II, and OCs of HLA-I [58]. Several studies documented that commercial IVIg inhibited PHA- or cytokine-induced T-cell activation and proliferation, both in vitro and in vivo [59–73].



Kaveri et al. [59] demonstrated that Abs to a conserved region of HLA-Ia, present in pooled therapeutic IVIg, were capable of modulating CD8+ T-cell-mediated function. Klaessn et al. [60] showed that IgG and F(ab)2 fractions in IVIg were responsible for the inhibitory function. In contrast, Miyagi et al. [61] attributed the inhibition of blastogenesis and proliferation of activated T-cells by IVIg to the Fc receptors for IgG, Fc γ RI (CD23), Fc γ RII (CD32), Fc γ RIII (CD16), and Fc γ RIV (CD64), expressed on the immune cells upon activation. MacMillan et al. [70] documented further the IVIg-mediated suppression of T-cell proliferation, with or without CD28 co-stimulation. Sali et al. [62] demonstrated that 2% intact or Fab₂ fragments of IVIg could penetrate immune cells to modulate these activities. The penetrating fraction of IVIg inhibited the upregulation of activation marker CD25 on CD4+ splenocytes. In a placebo-controlled trial, the administration of IVIg to patients with inflammatory myopathies was associated with a significant reduction of the number of T-lymphocytes in vivo [74].

Based on these observations, it was hypothesized that HLA-I polyreactive mAbs that mimicked HLA-I reactivity of IVIg preparations might suppress activated T-cells, similarly to IVIg. The hypothesis was tested by comparing dose-dependent effects on the suppression of PHA-activated T-cells of three entities: IVIg, HLA-I polyreactive mAbs that mimicked IVIg (TFL-006 and TFL-007), and mAbs that did not mimic IVIg (TFL-033 and TFL-037).

5.1.2. Hypothesis Testing: Measurement of T-Lymphocyte Proliferation


More details are presented elsewhere, but all experimental analyses were carried out at Terasaki Foundation Laboratory with Review Board approval [58]. Briefly, we labeled purified human T-lymphocytes (freshly collected from a healthy, young adult male) with the intracellular fluorescent dye Carboxyfluorescein N-succinimidyl ester (CFSE), a cell-permeable dye that remained in the cell for several mitotic divisions. The technology used is illustrated in Figure 6A. Most importantly, the cessation of the progress of mitotic activity could be monitored as successive two-fold reductions in the fluorescent intensity after 72 h of treatment, including the addition of PHA and PHA plus IVIg or mAbs [58].

Cell Proliferation measurements using Carboxyfluorescein succinimidyl ester (CFSE) staining method



(A)

Suppression of Blastogenesis and Proliferation of CD4+ and CD8+ T cells



(B)

Figure 6. (A). The proliferation assay is based on labeling the purified T-cells during PHA activation with the intracellular fluorescent dye carboxyfluorescein succinimidyl ester (CFSE: $C_{25}H_{15}NO_9$; mol. mass: 473.39 g/mol) and using flow cytometry, measuring mitotic activity by the successive twofold reductions in fluorescent intensity of the T-cells placed in culture for 72 h. CFSE is cell-permeable and is retained for long periods within cells by covalently coupling by means of its succinimidyl group to intracellular molecules. Due to this stable linkage, once incorporated within cells, CFSE is not transferred to adjacent T-cells but remains in the cell even after several mitotic divisions. (B). Suppression of blastogenesis and proliferation of CD4+ T-cells by IVIg (Globex) and HLA-I polyreactive mAb TFL-007 at similar protein concentrations. The CFSC profile illustrates suppression as indicated by asterisks.

5.1.3. The Suppression of Activated T-Cells by IVIg vs. mAbs

A summary of the findings is presented in Figures 6B, 7 and 8. The results established the differential effects on the suppression of PHA-activated T-cells, both by IVIg and by HLA-I polyreactive mAbs (TFL-006 and TFL-007). The mAbs (TFL-033 and TFL-037) that did not mimic the HLA-I reactivity of IVIg did not affect the activation or proliferation of T-cells. The mAbs TFL-006 and TFL-007 appeared to be more potent suppressors of the blastogenesis and proliferation of activated CD4+ T lymphocytes than IVIg. The concentrations of the mAbs required for the suppression of T-cell proliferation were 50-fold lower than the required concentration of IVIg. The suppression of blastogenesis and proliferation of T-cells by both IVIg and the anti-HLA-E mAbs was dose-dependent, and the dose required with mAbs was 50–150-fold lower than with IVIg. The mAb binding to OCs might have signaled T cell deactivation because the OCs have an elongated cytoplasmic tail with phosphorylation sites (tryosine320/serine335).




Figure 7. Suppression of PHA-activated CD4+ T-cells by HLA polyreactive monoclonals TFL-006 and TFL-007 at 1/10 dilutions. The control mAb, TFL-037, failed to suppress PHA-activated proliferation, whereas the HLA-I polyreactive mAbs suppressed proliferation significantly. Dosimetric suppression of TFL-007 is shown.




Figure 8. Suppression of proliferation of PHA-activated CD4⁺ T-cells by purified culture supernatant of anti-HLA-E mAb TFL-006s. Results of the triplicate analysis are presented. The numbers inside refer to cell counts. Refer to Figure 5A to understand the meaning of the shift in the profiles from right to left.

A tentative model of PHA-mediated activation and HLA polyreactive, mAb-mediated deactivation is proposed (Figure 9). It is known that PHA activation initiates phosphorylation of the cytoplasmic domain of CD3 and the activation of transcription factors. TCR cross-linking leads to the expression and phosphorylation of cell surface molecules such as IL-R α [74] and the OCs of HLA-I [13–22]. The binding of mAbs to the shared amino acid sequences or epitopes exposed on the OCs may dephosphorylate the tyrosyl and seryl residues on the elongated cytoplasmic tails of the HLA-I OCs [75,76]. This may simultaneously lead to dephosphorylation of CD3 and revert the PHA-activation of CD3 on T-cells (for further details, see the legend for Figure 9). Upon dephosphorylation, T-cells were deactivated, resulting in the suppression of blastogenesis and proliferation. Based on the observations that there was a suppression of the blastogenesis and proliferation of PHA-activated CD4⁺ T-cells by HLA-I polyreactive, anti-HLA-E mAbs (TFL-006 and TFL-007) but not by HLA-I non-reactive, anti-HLA-E mAbs (TFL-033 and TFL-007), it was inferred that the IVIg-mediated suppression of the blastogenesis and proliferation of PHA-activated CD4⁺ T-cells could also be due to binding of the HLA-I OC-reactive IgG fraction in IVIg. Furthermore, when equal concentrations of the HLA-I polyreactive mAb TFL-007 and IVIg were compared, the suppression by the mAbs was greater than that of the IVIg. Evidently, the admixture of other IgGs with HLA-polyreactive IgGs in IVIg might have hindered the T-cell suppressive efficacy of the IVIg.




Figure 9. A model illustrating the possible mechanism underlying phytohemagglutinin (PHA) activation of T-cells and the suppression of activated T-cells mediated by HLA-I polyreactive mAbs (TFL-006 and TLF-007) and possibly by IVIg. The model is based on a model proposed by Mustelin, Vang, and Bottini [77] for T-cell activation. The CD3/T-cell receptor (TCR)/CD4 structure on the lipid raft (pink zone) of the bi-layered lipid membrane on the non-phosphorylated, non-activated CD4+ T-cells is illustrated. The lymphocyte-specific protein, tyrosine kinase (LCK), induced phosphorylation of tyrosine-based activation in the cytoplasmic domain of CD3, which led to the activation of transcription factors and the transcription of cell surface molecules such as interleukin (IL)-2R α and open conformers of HLA class I. SH-1, SH-2, and SH-3 represent family members of Src homology; they are involved in mediating the cytoplasmic domain of CD3. Further activation of the tyrosyl-phosphorylated motifs and then interaction with SH-1 domains within the protein kinase LCK led to further signaling function [77]. Importantly, the exposure of shared amino acid sequences of all the HLA open conformers is indicated by a blue circle. It is this site that is recognized by TFL-006 and TFL-007. Possible interactions and consequences of recognition of the shared peptide sequences by the HLA-I polyreactive IgG mAbs are illustrated in three steps: first, the exposure of the shared peptide sequence on the open conformer; secondly, recognition of the shared epitopes on the open conformer by the mAbs; thirdly, possible phosphorylation of the elongated cytoplasmic tail of open conformers. That elongation resulted in the exposure of cryptic tyrosine (Tyr320) and serine (Ser355) residues in the cytoplasmic tail. It might have been the binding of the mAbs to the shared peptide sequences that initiated the phosphorylation, leading to signal transduction. A final step involved initiation of dephosphorylation of the cytoplasmic domain of CD3, resulting in arrest of activation or suppression. That seemed plausible, as the phosphorylation was known to be reversible.

5.2. Suppression of Antibody Production by B-Cells: IVIg vs. HLA-I Polyreactive mAbs

5.2.1. Background and Hypothesis

Previous literature documented that commercial IVIg not only inhibited PHA- and cytokine-induced T-cell activation and proliferation and significantly reduced the number of T-lymphocytes *in vivo* in a placebo-controlled trial in patients with inflammatory myopathies, but it was also capable of suppressing antibody production in patients under different disease conditions. Therefore, IVIg has become not only a substitution therapy for patients with immunodeficiencies [78], but also a therapeutic agent in autoimmune and systemic inflammatory diseases [79], as well as in organ and bone marrow transplantation [3,80].

IVIg is extensively used in patients with end-stage organ disease as well as allograft recipients. High levels of HLA antibodies, caused by various sensitizing events such as previous transplantation, pregnancy, or blood transfusion, are observed in patients with end-stage organ disease. High levels of such allo-HLA Abs can more likely produce positive crossmatch results with potential organ donors and preclude transplantation. Consequently, antibody-positive patients may experience prolonged waiting time. Among renal transplant recipients alone, such sensitized patients constitute more than one-third of those on the waiting list. For highly sensitized patients (with a panel-reactive HLA antibody (PRA) greater than 80%), the prospects of transplantation are grim.

The formation of Abs against allo-antigens depends on both T and B-cells. Therefore, aggressive suppressive strategies have been developed to deplete both T and B-cells in order to reduce the generation of allo-HLA Abs formed before and after transplantation. One such strategy is induction therapy with rabbit or horse anti-human thymocyte globulin, a polyreactive, polyclonal mixture of non-specific cytotoxic Abs capable of killing immune cells [81]. However, many clinical transplant centers worldwide have formulated alternate protocols to suppress the formation of anti-HLA Abs. These protocols may include plasmapheresis (PP), high-dose IVIg, or a combination of PP with low-dose IVIg [2,49–54,82–87] or Rituximab, a monoclonal Ab (mAb) that depletes CD20+ B-cells [88–91]. Although several immunotherapeutic potentials are attributed to IVIg, its mechanism of action is far from certain. Possibly, it is due to polyclonality and the mixture of several kinds of IgG Abs present, including Abs against all HLA class I loci and alleles, as illustrated in Table 6, and Figure 5A,B.

A most interesting finding [35] was that the HLA-Ia reactivity of IVIg was significantly abolished when anti-HLA-E Abs were depleted, specifically by passing IVIg through HLA-E heavy chain-conjugated Affi-gel affinity columns. This suggested that IVIg's HLA-Ia reactivity could possibly be due to the presence of HLA-E-specific IgG Abs, and that there were anti-HLA-E mAbs that might simulate the HLA reactivity of IVIg.

These observations led us to hypothesize that the anti-HLA-E mAbs that simulated the HLA-reactivity of IVIg could mimic IVIg by suppressing B-cells from producing Abs. We compared the efficacy of IVIg versus that of mAb TFL-007 (HLA-I polyreactive, anti-HLA-E mAb) (Table 4) in suppressing the B-cell blastogenesis, proliferation, and production of Abs.

5.2.2. Methodology to Test the Hypothesis

More details are presented elsewhere [92]. Two commercial IVIg preparations were used. They were (1) IVIg-GamaSTAN™ (Lot 26NJ651; Talecris Biotherapeutics, Inc., Research Triangle Park, NC, USA) formulated as a 15–18% protein solution at a pH of 6.4–7.2 in 0.21–0.32 M glycine and, (2) IVIgGamunex®-C (Lot 26NKL1, Talecris), a solution at a pH of 6.4–7.2 in 0.16–0.24 M glycine, albumin < 20 µg/mL. The HLA-I polyreactive HLA-E mAbs used were TFL-007s (culture supernatant) and TFL-007a (ascites). For suppressing antibody production by B-cells, two different experiments were carried out:

Experiment # 1 was on freshly purified B-cells from the peripheral blood lymphocytes of a woman alloimmunized with her husband's HLA DRB1*0101 antigens during her first pregnancy.

The HLA typing of the woman, her husband, and their two daughters (first, 23 years; second, 18 years) revealed that both the father and the first daughter carried the DRB1*0101 allele, while the mother's sera showed the prevalence of high levels of allo-antibody against DRB1*0101. Periodic screening indicated that the high MFIs of the primary allo-HLA Abs had persisted for the past two years. Most likely, the anti-DRB1*0101 IgG Abs with high MFI were formed as a consequence of alloimmunization during a pregnancy that occurred 23 years before, which suggested the prevalence of both long-lived memory B-cells and bone marrow-resident plasma cells. Because this alloantibody was bound to the husband's primary allele, the antibody was designated as the 'primary alloantibody'.

Therefore, her peripheral blood B-cells were isolated and purified after obtaining her informed consent and institutional (TFL) approval. The B-cells were purified from the PBMC by positive selection, using CD19 Pan B Dynabeads® magnetic beads (Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA), and detached using DETACHaBEAD® CD19 (Invitrogen). Purified B-cells (>95% CD19+) were plated at $0.2 \times 10^6/200$ µL/well in a sterile, 96-well plate (ThermoFisher Scientific, Inc., Waltham, MA, USA) and cultured in Iscove's Modified Dulbecco's medium, containing HEPES, L-glutamine, and sodium pyruvate (Gibco-Invitrogen) supplemented with AB human serum (10%), recombinant human (rh) insulin (5 µg/mL), rh-transferrin (50 µg/mL), gentamycin (25 µg/mL), and 2-mercaptoethanol (50 µM). The resting B-cells were activated with rh-IL-2 (50 ng/mL), rhIL-4 (100 ng/mL), rhIL-6 (100 ng/mL), rhIL-10 (50 ng/mL), and human CD40 antibody (1 µg/mL) [92]. The B-cell population (CD19+)

isolated from PBMC, using positive selection on day 0, consisted of a major fraction including naive B-cells (CD20+/CD27−/CD38+/-) (74.47%), B-memory cells (CD20+/CD27+/CD38−) (8.47%), and plasma cells (CD20−/CD27+/CD38++) (0.26%). These cells, upon activation by the selected battery of cytokines IL-2/IL-4/IL-6/IL-10/IL-21 (at a 1:4:4:2:2 ratio) and human CD40 antibody (1 µg/mL) for seven days, resulted in an increase in plasma cells from 0.26% on day 0 to 36.25% on day 7. On day 7, culture supernatants [10 µL] from each well were analyzed for anti-HLA, class II IgG alloAbs. Cells from the positive wells were further harvested, washed (3x), seeded, and activated again as above. On days 8 and 9, the culture supernatants were screened for Abs. After ascertaining the consistency of the MFIs of the Abs on days 8 and 9, the cells were pooled, washed (3X), and aliquoted. They were maintained in culture without any cytokine activators or anti-CD40 antibody for an additional 3 days. The culture supernatants [10 µL] from each well were analyzed for Abs at 0, 12, 24, 48, and 72 h.

On day 9, the cells were pooled, aliquoted, and maintained without the cytokine combo or anti-CD40 mAb. These wells were exposed to medium or IVIg (1/100, 1.5 mg/mL) or mAb TFL-007s (1/100, 5 µg/mL) for 72 h. To study the effect of IVIg on the secretion of allo-HLA IgG Abs, we used IVIg at a protein concentration 300-fold higher than that of the purified culture supernatant of TFL-007s (5 µg/mL) used in the treatment of B-cells in culture. The supernatants recovered from the respective wells were screened for the HLA-alloAbs.

Experiment # 2 was on the human hybridoma cell line HML16, generated from the resting B-cells of a multiparous woman.

The human hybridoma cell line, HML16, produced anti-HLA, class I alloAbs with differing MFIs: high against B*0702, B*8101, B*6701, and B*4201; and low against B*2708, B*2705, B*5501, B*5601, and B*8201. The cell line was cultured in RPMI-1640, as described earlier. The cells were seeded at 1000/100 µL/well in a Falcon 96-well, flat-bottomed plate and divided into different treatment groups: Group 1, medium control; Group 2, mouse IgG control; Group 3, mAb TFL-007 (ascites); Group 4, IVIg (GamaSTAN); and Group 5, IVIg (Gamunex-C). The following sub-groups were established: mouse IgG control (100 and 50 µg/mL); GamaSTAN–IVIg subgroups were at dilutions 1:10 (15 mg/mL), 1:20 (7.5 mg/mL), and 1:40 (3.75 mg/mL); Gamunex-IVIg subgroups were at dilutions 1:10 (10 mg/mL), 1:20 (5 mg/mL), and 1:40 (2.5 mg/mL); and mAb TFL-007a subgroups were at dilutions 1:10 (100 µg/mL), 1:20 (50 µg/mL), 1:40 (25 µg/mL), and 1:80 (12.5 µg/mL). Twenty µL of culture supernatant from each well were analyzed for allo-HLA Abs at 0 and 72 h.

The expression of CD19 was monitored using the fluorescein isothiocyanate (FITC)-labeled, anti-human CD19 (mAb HIB19). On days 0 and 7, both resting and activated B-cells were stained with phycoerythrin (PE) anti-human CD20 (mAb 2H7), peridinin chlorophyll (PerCP) antihuman CD27 (mAb 0323), and FITC anti-human CD38 (mAb HIT2) to examine the differential activation of B-cells. The source of the mAbs was from BioLegend. Prior to staining with Abs, Human TruStain FcX™ (BioLegend, San Diego, CA, USA) was used to block FcR-involved, unwanted staining.

5.2.3. TFL-007 Suppressed HLA-Antibody Production Better Than That of IVIg

In the first experiment, both the sera of the woman and of those secreted by activated memory B-cells (culture supernatants) showed the presence of several alloAbs directed against DRB1*0102, DRB1*0404, DRB1*0405, DRB1*1402, and DRB1*0401, in addition to the primary alloantibody, anti-DRB1*0101 IgG. The secondary alloAbs were not directed against the husband's alleles. They might have represented cross-reactive alloAbs in that they occurred in cultures containing the primary alloantibody, anti-DRB1*0101. These alleles shared amino acids or amino acid sequences with the primary allele, DRB1*0101. The details were presented elsewhere [92].

Figure 10 documents that the GamaSTAN IVIg suppressed the secretion of the primary alloantibody against DRB1*0101 at different time points ($p^2 < 0.01$). Similarly, the HLA

polyreactive mAb TFL-007s also significantly reduced the secretion of the primary alloantibody ($p^2 < 0.0005$). However, the suppression of the secretion of the primary alloantibody by the mAb TFL-007s was highly significant compared to the IVIg-induced suppression.




Figure 10. The impact of IVIg (GamaSTAN) and HLA-I polyreactive mAb (TFL-007) on the primary alloantibody DRB1*0101 (IgG), secreted by activated B-lymphocytes obtained from an alloimmunized woman. GamaSTAN S/D IVIg was used at 1:100 dilution, 1.5 mg. protein/mL. At the time when the IVIg was added, the cytokine combo and anti-CD40 antibody were not added. In all panels, the mean fluorescent intensity (MFI) of alloantibody secretion is compared between the medium control and treatment with IVIg and HLA-I polyreactive IgG2a mAb TFL-007. IVIg inhibited the secretion of the primary alloantibody at a significant level ($p^2 = 0.01$). HLA-I polyreactive mAb inhibited the secretion of the primary alloantibody at a higher significant level ($p^2 = 0.0005$). This is an original figure.

In the second experiment, the treatment effects of two preparations of IVIg (GamaSTAN and Gamunex) were tested on HM16 at different dilutions and protein concentrations and compared with the media control [92]. The IVIg concentration used for the hybridoma cell line HML16 was comparable to the high-dose IVIg used for desensitization and post-transplant therapy. Neither of the IVIg preparations showed any significant suppression of the secretion of allo-HLA-B IgG by the hybridoma cells. In contrast, the mAb TFL-007a had a strikingly significant suppressive effect on the secretion of both HLA-B*0702 and B*8101. More importantly, the mAb TFL-007a showed dosimetric suppression of allo-HLA Abs. When HML16 was treated with the highest concentration of TFL-007a (100 $\mu\text{g}/\text{mL}$), suppression was 33% for B*0702 and 34% for B*8101, compared with the medium control group. When the dosage of TFL007a was decreased, the suppression effect declined. In short, in marked contrast to the IVIg preparations, the HLA-I polyreactive mAb TFL-007a significantly suppressed the secretion of both allo-HLA-B Abs.

5.3. Expansion of *Foxp3*⁺ Tregs *In Vitro*: IVIg versus HLA-I Polyreactive mAbs

Human CD4⁺CD25⁺*Foxp3*⁺ regulatory T-cells are a naturally occurring population of regulatory T-cells (Tregs) in circulation [93,94]. Their presence in liver allografts is attributed to tolerance of the transplanted organ [95–101]. They suppress Ab production

by downregulating B memory and plasma cells [102] and depleting both CD4+ [103] and CD8+ [104,105] T-cells, and hence, they play a major role in graft tolerance [101,106,107]. While performing skin graft experiments on human-CD52 transgenic CP1-CBA/Ca (H-2^k) mice, Garca et al. [106] observed that the “T cell suppression of graft rejection is an active process that operates beyond secondary lymphoid tissue, and involves the persistent presence of regulatory T-cells at the site of the tolerated transplant.” (p. 1641).

The therapeutic mAb, tocilizumab, given to patients with rheumatoid arthritis, increases T-regs and correlates with clinical response [108]. Upregulation of T-regs by IVIg is considered a critical factor in controlling experimental autoimmune encephalomyelitis; IVIg is known to upregulate T-regs [109].

Because IVIg can upregulate T-regs, it is hypothesized that the HLA-I polyreactive mAbs TFL-006 and TFL-007 may also induce proliferation of T-regs. For testing this hypothesis, CD4+CD25+foxp³+ Tregs were obtained from the peripheral blood of normal and healthy donors after obtaining necessary consent and institutional IRB approval. A variety of cell surface markers, including CD4, CD25 (IL-2R α), CD45RA, and FoxP3, were monitored, using their respective monoclonal Abs.

We compared the impact of different commercial preparations of IVIg and the HLA-I polyreactive mAb TFL-007 in triplicate on untreated T-regulatory cells (CD4+/CD25+/FoxP3⁺) obtained from the blood of a healthy volunteer from TFL. The mAb purified from ascites was used throughout. Figure 11 illustrates that the different commercial preparations of IVIg at two different dilutions (1/10 and 1/80) failed to upregulate the Tregs, while the mAb TFL-007a showed a significant increase in the number of cells as compared to controls.




Figure 11. Effects of different commercial preparations of IVIg, which included GamaSTAN™ S/D (15–18 gm%, Lot 26NHCVI; Talecris Biotherapeutics, Inc., Research Triangle Park, NC, USA) at dilutions 1/10 (concentration 15 mg/mL) and 1/80 (concentration 1.2 mg/mL), octagam® (6 gm%, Lot A913A8431; Octapharma Pharmazeutika) at dilutions 1/20 (concentration 3 mg/mL) and 1/80 (concentration 0.75 mg/mL), Gamunex®-C (10 gm%, Lots 26NKLGI and 26NKLK1; Telacris) at dilutions 1/10 (concentration 10 mg/mL) and 1/80 (concentration 8 mg/mL), and mAb TFL-007a (at dilution 1/10, concentration 62.7 µg/mL; 1/80, concentration 7.84 µg/mL) on PHA-untreated cells were compared with the effect of medium alone on the proliferation of Treg cells, defined as CD4+/CD25+/Foxp³+. Note that IVIg preparations used in this study failed to upregulate Tregs, in contrast to TFL-007a, which significantly upregulated Treg cells at dilution 1/10. This figure is original but derived and modified from a previous report [48].

6. Discussion

IVIg is a mixture of polyclonal IgG Abs, pooled and purified from thousands of normal individuals. The binding affinity of IVIg is multivarious because the IgG Abs in IVIg can bind to blood groups, MHC complex antigens, cytokines, chemokines and their receptors, and several other antigens including human albumin. Most importantly, in the last three decades [2,3,49–57,82–91], IVIg has been administered to HLA-sensitized patients who possess a higher level of HLA allo-Abs, with the intention to lower these Abs. Due to the high level of these allo-HLA Abs, such patients are more likely to have a positive crossmatch result with potential organ donors pre-transplantation, and they often languish for years on the waiting list. For highly sensitized patients, the prospects of transplantation get grim. Realizing the imminent need to lower the impact of HLA sensitization, the US FDA approved IVIg for therapeutic administration in HLA-sensitized patients. However, due to its lack of efficacy as a monotherapy [55–57], IVIg is often combined with other therapeutic agents [89–91] such as plasmapheresis and rituximab (a mAb that depletes CD20+ B-cells). Commercial therapeutic preparations of IVIg, formulated in different countries, possess allo-HLA IgG Abs against almost all alleles of all six loci of HLA-I [35,57]. In this regard, HLA polyreactive mAbs developed from HLA-E α HCs mimic the allo-HLA antibody profile of IVIg [the U.S. Patent 10,800,847; 13 October 2020].

The structure of a single HLA-I antigen has two different profiles, as illustrated in Figure 2. The most well-known profile is the cell surface heteromer, consisting of α -HC associated with β 2m (Figure 1). In the heteromeric profile, many of the most commonly shared amino acid sequences (Tables 1 and 2), such as ¹¹⁷AYDGKDY¹²³ and ¹²⁷LNEDLRSWTA¹³⁵ are cryptic, hidden by β 2m. The second less-known profile of a single HLA-I antigen is a β 2m-free α -HC, i.e., an OC (Figure 2). Although this structure is naturally occurring, it is often misconstrued to be identical to denatured HLA antigens, as found on alkali or acid-treated SABs [46,110]. In fact, the misconception that the monomeric versions of naturally occurring HLA molecules are “denatured” HLA is well-documented in several reports [13–30]. These reports demonstrate several novel aspects of the monomeric versions. The shared amino acid sequences common to all six loci of HLA are exposed for immune recognition and serve as receptors for signal transduction. Notably, the long cytoplasmic tails of the monomeric versions on cells with tyrosyl and seryl residues (Figure 2) are shown to be involved in signal transduction (Figure 9). Arosa et al. [19,111] elucidated further the difference between the intact HLA antigens, as CCs, and the monomeric variants, as OCs, when expressed in vivo on the cell surface (Figure 4). One difference was that HLA molecules shed from the cell surface [112] occurred as monomeric variants, or OCs, in the circulation (Figure 3). Since they exposed cryptic epitopes, they served as immunogens for allo-HLA Ab production. Indeed, the immunogenicity and antigenicity of the shared cryptic epitope ¹¹⁷AYDGKDY¹²³ were much greater than other epitopes (Table 2).

Visualizing the antibody recognition sites (epitopes) of CCs and OCs would clarify and elucidate the HLA profile instrumental for generation of HLA-I polyreactive IgG mAbs and naturally occurring IgG Abs. Theoretically, one can expect the presence of polyreactive IgG Abs recognizing the OCs of HLA in IVIg. Indeed Figure 5 confirms the prevalence of two commercial preparations of IVIg reacting to monomeric variants on the acid denatured SABs. The density of IgG binding to monomeric variants was much higher than those recognizing the CCs on ‘iBeads’ (Figure 5). Kaveri et al. [59] pointed out “Abs to a conserved region (cryptic domain) of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use” (p. 865). Strikingly, HLA-polyreactive IgG2a mAbs (TFL-006 and TFL-007) do not recognize CCs, but recognize only the OCs on the SABs (Table 5). Importantly, as noted above, these naturally occurring OCs existing on the cell surface in vivo should not be considered synonymous with chemical treatment (acid or alkali) on synthetic beads disrupting intact CCs to produce denatured α -HCs in vitro.

The binding of the HLA-I polyreactive mAbs to OCs is responsible for the suppression of blastogenesis and proliferation. It may involve the reversal of phases of activation

of T-lymphocytes, mediated by signal transduction. The elongation of the cytoplasmic tail of the HLA-I OCs exposes otherwise cryptic tyrosine-320 [76] and serine-335 [113] residues, with a provision for phosphorylation (Figure 9). Although serine-335 is generally considered the primary site of phosphorylation in this tail, the phosphorylation of tyrosine-320 has been indicated by others [76]. Thus, the HLA-I OCs in activated T-cells are associated with tyrosine phosphorylation and are capable of enabling cis interactions with cell surface receptors or other signaling molecules [76,77,113–116]. The binding by TFL mAbs may result in dephosphorylation of the cytoplasmic tails of CD3 molecules by activating phosphatases. The result is to arrest transcription factors and inhibit the synthesis of the proteins involved in blastogenesis and mitosis (Figure 9). These events suggest that the suppression of the activation of T-cells could be due to the binding of HLA-I polyreactive mAbs, mimicking the HLA-I polyreactivity of IVIG, to the shared amino acid sequences exposed on the naturally occurring OCs of HLA-I molecules (Figure 2). This activation involves not one HLA-I locus but all alleles of the six loci (HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G) expressed on the surface of activated T-cells. The efficacy of the monoclonality of the HLA-I polyreactive mAbs and their F(ab')₂ binding is restricted to OCs. Furthermore, poor efficacy of IVIg is due to admixture with CC-binding Abs, other non-HLA Abs, anti-idiotypic Abs, immune complexes, and other chemicals such as sugars added to render stability to IVIg.

Possibly, the same or similar phosphorylation and dephosphorylation mechanisms may be involved in suppressing antibody production by B-cells. The HLA-I polyreactive mAb, but not IVIg, suppressed allo-HLA-I and allo-HLA-II Abs production by B-memory cells and immortalized B-cells. While monitoring the efficacy of the HLA-I polyreactive mAbs, the cytokine combination and anti-CD40 antibody were both removed to precisely evaluate the impact of the antibody. Possibly, HLA-I polyreactive mAbs may also help to suppress other Abs produced by B-cells and alloAbs as well.

In addition, the HLA-I polyreactive mAbs upregulated T-regs better than IVIg (Figure 11). T-regs are well known for their immunoregulatory properties. They suppress Ab production by downregulating B-memory and plasma cells [102] and by depleting CD4+ [103] and CD8+ [104,105] T-cells. We believe that both IVIg and the HLA-I polyreactive TFL mAbs perform the immunosuppressive functions stated above, including the upregulation of T-regs, by binding to the OCs of HLA.

7. Conclusions

The observations point out conclusively that IVIg (a) suppressed blastogenesis and proliferation of T-cells, (b) minimized the HLA-II allo-antibody production by B-memory cells of parous women and HLA-I antibody production of an immortalized cell line, and (c) expanded T-regs. These effects could be due to the HLA OC-polyreactive Abs present in IVIg. These findings are further strengthened by the several similarities observed in the nature and functional characteristics of IVIg and HLA-I polyreactive, OC-specific TFL mAbs (TFL-006 and TFL-007) (Table 7). The mAbs, which recognize shared epitopes on naturally occurring OCs, with no ability to bind to the CCs, perform the same suppressive functions better than the different preparations of IVIg. Possibly, anti-CC Abs present in IVIg may impact their above-mentioned immunomodulatory functions. Hence, HLA-I polyreactive TFL mAbs are capable of serving as IVIg-mimetics, perhaps more efficiently than IVIg itself. Clinical trials are clearly warranted. Possibly, humanized versions of these TFL-mAbs, either combined or alone, can be better therapeutic tools than IVIg to suppress HLA sensitization and minimize antibody production post-transplantation.

Table 7. Comparison of natural and functional characteristics of IVIg and HLA-I polyreactive mAbs.

Source, Nature, and Functions	Intravenous Immunoglobulin (IVIg)	HLA-I Polyreactive mAbs, TFL-006 & TFL-007
Manufacturer	Several pharmaceutical firms	Terasaki Foundation Laboratory, U.S. Patent No. 10,800.847;10/13/20
Source	Purified from pooled plasma of 10,000 blood donors	Immunized in mice with a heavy chain of HLA-E ^{R107}
Nature of antibody	Human, polyclonal IgG with trace levels of IgA	Murine purified monoclonal IgG
Subclass of IgG antibodies	IgG1, IgG2a, IgG3, IgG4	IgG2a
Purity	Contains soluble HLA antigens and other non-IgG proteins	100% purified protein of IgG2a [44,45]
Antibody reactivity	Cytokines, chemokines	
	CCs & OCs of HLA-A, HLA-B, HLA-Cw, HLA-E, HLA-F	OCs but not CCs of HLA-A, HLA-B, HLA-Cw, HLA-E, HLA-F, HLA-G
	HLA-G, HLA-DR, HLA-DQA/DQB, HLA-DPA/DPB	None
	Fc receptors: FcγI, FcγII, FcγIII, FcγIV (tested) [96]	FcγII (anticipated)
	Blood groups: A, B, Rh	No
	<i>Escherichia coli</i> bacterial antigens ranging from	No
	antigens by different preparations of IVIg	No
Binding site	Human albumin	No
	Phospholipids	No
	Binds to both closed and open conformers	Binds only to open conformers
	Stabilizer	Many, including sucrose in some preparations
Protein concentration	Highly variable, from 2 to 12%	Protein concentration adjusted to requirement
CD4+ T-cell suppression	PHA- or cytokine-activated T cells by apoptosis and necrosis	PHA-activated T cells
CD8+ T-cell proliferation	PHA-activated T-cells	PHA-activated T cells
B-cell proliferation	May induce differentiation	None
Anti-HLA antibody suppression	PRA antibody reduction	Suppress production of anti-HLA-I and anti-HLA-II IgG
	Suppress selected HLA-II antibody production	
	Promote selected HLA-II antibody production	
Expansion of Tregs	Yes	Yes
Special application	Not applicable	To monitor the presence of open conformers admixed with
		closed conformers on the bead sets. (e.g., LABScreen vs
		LIFECODE bead sets used in monitoring HLA antibodies

Author Contributions: All authors jointly studied the literature and formulated the concept of the review, after discussions. The first author generated the first version of the review, which further developed by the other two authors. The third author extensively revised the final version from the clinical perspective. All authors have read and agreed to the published version of the manuscript.

Funding: This research utilizes the funds received from Mark Terasaki, first son of Late Prof. Paul Terasaki and Terasaki Foundation Laboratory.

Institutional Review Board Statement: This article is a review based on two major in vitro investigations carried out by Terasaki Foundation Laboratory, which resulted in two original research articles (58, 92). Healthy sera of TFL volunteers and on sera from Japan was obtained by Late Terasaki after obtaining informed consent. The experiments were conducted between 2013 and 2015, according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Terasaki Foundation laboratory. TFL is not affiliated with any universities or hospitals and it is a private research institute. For details, refer to the original publications (58, 92). The hybridomas of the mAbs were raised at One Lambda Inc in 2012, owned by Late Paul Terasaki, It had animal research approval.

Informed Consent Statement: TFL has obtained informed consents from a normal and healthy male (T cell studies [58]) and from a normal healthy mother (B cell study [92]) of working at TFL between 2013–2015.

Data Availability Statement: Data are available with the first author of each investigation [58,92] /./;[-00,847; 13 October 2020).

Acknowledgments: The experiments reported in this review were carried out at Terasaki Foundation Laboratory in Santa Monica, California with the guidance of the late Paul Ichiro Terasaki, and with the active and enthusiastic involvement of several dynamic research associates. Luminex Single Antigen Bead immunoassays for monitoring HLA-I reactivities of IVIg and the TFL mAbs and the experiments related to CD4+ T-cells were assisted by the following research associates: Tho Pham, Vadim Jucaud, and Satoru Kawakita; the experiments related to B-cells were carried out by Dong Zhu, T. Miyazaki, ‡ Tho Pham, and Vadim Jucaud; and the experiments related to T-regs were performed by Michiko Taniguchi. The current report has been encouraged and financially supported by the funds from Mark Terasaki, first son of the late Paul Terasaki. The first author (MHR) dedicates this review to his mentor, the late Paul Ichiro Terasaki, whose constant discussions, both at his office and at weekly seminar, molded the thought process for this review. In addition, Terasaki is a co-inventor, with the first author, of the patent entitled Anti-HLA class-Ib antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIg) useful as therapeutic IVIg mimetics and methods of their use. (U.S. Patent 10,800,847; 13 October 2020).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Darabi, K.; OAbdel-Wahab, O.; Dzik, W.H. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. *Transfusion* **2006**, *46*, 741–753. [[CrossRef](#)]
2. Glotz, D.; Haymann, J.-P.; Sansonetti, N.; Francois, A.; Menoyo-Calonge, V.; Bariety, J.; Druet, P. Suppression of HLA-specific alloAbs by high-dose intravenous immunoglobulins (IVIg). *Transplantation* **1993**, *56*, 335–337. [[CrossRef](#)] [[PubMed](#)]
3. Tyan, D.B.; Li, V.A.; Czer, L.; Trento, A.; Jordan, S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. *Transplantation* **1994**, *57*, 553–562. [[CrossRef](#)]
4. Sapir, T.; Shoenfeld, Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. *Clin. Rev. Allergy Immunol.* **2005**, *29*, 185–199. [[CrossRef](#)]
5. Tongio, M.M.; Falkenrodt, A.; Mitsuishi, Y.; Urlacher, A.; Bergerat, J.P.; North, M.L.; Mayer, S. Natural HLA Abs. *Tissue Antigens.* **1985**, *26*, 271–285. [[CrossRef](#)] [[PubMed](#)]
6. Luscher, M.A.; Choy, G.; Embree, J.E.; Nagelkerke, N.J.; Bwayo, J.J.; Nienga, S.; Plummer, F.A.; Barber, B.H.; MacDonald, K.S. Anti-HLA alloAb is found in children but does not correlate with a lack of HIV type 1 transmission from infected mothers. *AIDS Res. Hum. Retrovir.* **1998**, *14*, 99–107. [[CrossRef](#)]
7. Morales-Buenrostro, L.E.; Terasaki, P.I.; Marino-Vazquez, L.A.; Lee, J.-H.; El-Awar, N.; Alberú, J. “Natural” human leukocyte antigen Abs found in nonalloimmunized healthy males. *Transplantation* **2008**, *86*, 1111–1115. [[CrossRef](#)] [[PubMed](#)]
8. Zhou, B.; Saito, S.; Nakazawa, Y.; Kobayashi, N.; Matsuda, M.; Matsumoto, Y.; Hosoyama, T.; Koike, K. Existence of an immunoglobulin G component of naturally occurring HLA class I Abs that are not directed against self-antigens in human serum. *Tissue Antigens.* **2008**, *72*, 98–104. [[CrossRef](#)]

9. Ravindranath, M.H.; Kaneku, H.; El-Awar, N.; Morales-Buenrostro, L.E.; Terasaki, P.I. Abs to HLA-E in alloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. *J. Immunol.* **2010**, *185*, 1935–1948. [[CrossRef](#)]
10. Ravindranath, M.H.; Taniguchi, M.; Chen, C.W.; Ozawa, M.; Kaneku, H.; El-Awar, N.; Cai, J.; Terasaki, P.I. HLA-E mAbs recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA Abs. *Mol. Immunol.* **2010**, *47*, 1121–1131. [[CrossRef](#)]
11. Ravindranath, M.H.; Pham, T.; El-Awar, N.; Kaneku, H.; Terasaki, P.I. Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the Abs. *Mol. Immunol.* **2011**, *48*, 423–430. [[CrossRef](#)]
12. Marsh, S.G.E.; Parham, P.; Barber, L.D. *The HLA Facts Book*; Academic Press: San Diego, CA, USA, 2000; 400p.
13. Schnabl, E.; Stockinger, H.; Majdic, O.; Gaugitsch, H.; Lindley, I.J.; Maurer, D.; Hajek-Rosenmayr, A.; Knapp, W. Activated human T lymphocytes express MHC class I heavy chains not associated with beta 2 m. *J. Exp. Med.* **1990**, *171*, 1431–1442. [[CrossRef](#)]
14. Schumacher, T.N.; Heemels, M.T.; Neefjes, J.J.; Kast, W.M.; Melief, C.J.; Ploegh, H.L. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. *Cell* **1990**, *62*, 563–567. [[CrossRef](#)]
15. Benjamin, R.J.; Madrigal, J.A.; Parham, P. Peptide binding to empty HLA-B27 molecules of viable human cells. *Nature* **1991**, *351*, 74–77. [[CrossRef](#)]
16. Majdic, O.; Schnabl, E.; Stockinger, H.; Gadd, S.; Maurer, D.; Radaszkewics, T. LA45, an activation-induced human lymphocyte antigen with strong homology to MHC class I molecules. In *Leukocyte Typing IV*; Oxford University Press: Oxford, UK, 1989; Volume 511, 8p.
17. Madrigal, J.A.; Belich, M.P.; Benjamin, R.J.; Little, A.M.; Hildebrand, W.H.; Mann, D.L.; Parham, P. Molecular definition of a polymorphic antigen (LA45) of free HLA-A and -B heavy chains found on the surfaces of activated B and T-cells. *J. Exp. Med.* **1991**, *174*, 1085–1095. [[CrossRef](#)]
18. Santos, S.G.; Simon, J.; Powis, S.J.; Arosa, F.A. Misfolding of Major Histocompatibility Complex Class I Molecules in Activated T-cells Allows cis-Interactions with Receptors and Signaling Molecules and Is Associated with Tyrosine Phosphorylation. *J. Biol. Chem.* **2004**, *279*, 53062–53070. [[CrossRef](#)] [[PubMed](#)]
19. Arosa, F.A.; Santos, S.G.; Powis, S.J. OC: The hidden face of MHC-I molecules. *Trends Immunol.* **2007**, *28*, 115–123. [[CrossRef](#)]
20. Demaria, S.; Schwab, R.; Bushkin, Y. The origin and fate of beta 2m-free MHC class I molecules induced on activated T-cells. *Cell Immunol.* **1992**, *142*, 103–113. [[CrossRef](#)]
21. Demaria, S.; Bushkin, Y. CD8 and beta-2 m-free MHC class I molecules in T cell immunoregulation. *Int. J. Clin. Lab. Res.* **1993**, *23*, 61–69. [[CrossRef](#)] [[PubMed](#)]
22. Raine, T.; Brown, D.; Bowness, P.; Hill Gaston, J.S.; Moffett, A.; Trowsdale, J.; Allen, R.L. Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthritis patients point to physiological and pathological roles. *Rheumatology* **2006**, *45*, 1338–1344. [[CrossRef](#)] [[PubMed](#)]
23. Allen, R.L.; O’Callaghan, C.A.; McMichael, A.J.; Bowness, P. Cutting edge: HLA-B27 can form a novel beta2m-free H chain homodimer structure. *J. Immunol.* **1999**, *162*, 5045–5048. [[PubMed](#)]
24. Khare, S.D.; Hansen, J.; Luthra, H.S.; David, C.S. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2m (beta2m) double transgenic mice with disrupted mouse beta2m. *J. Clin. Invest.* **1996**, *98*, 2746–2755. [[CrossRef](#)] [[PubMed](#)]
25. Capps, G.G.; Robinson, B.E.; Lewis, K.D.; Zúñiga, M.C. In vivo dimeric association of class I MHC heavy chains. Possible relationship to class I MHC heavy chain-beta 2m dissociation. *J. Immunol.* **1993**, *151*, 159–169. [[PubMed](#)]
26. Matko, J.; Bushkin, Y.; Wei, T.; Edidin, M. Clustering of class I HLA molecules on the surfaces of activated and transformed human cells. *J. Immunol.* **1994**, *152*, 3353–3360.
27. Allen, R.L.; Raine, T.; Haude, A.; Trowsdale, J.; Wilson, M.J. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. *J. Immunol.* **2001**, *167*, 5543–5547. [[CrossRef](#)]
28. Demaria, S.; Schwab, R.; Gottesman, S.R.; Bushkin, Y. Soluble beta 2-m-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. *J. Biol. Chem.* **1994**, *269*, 6689–6694. [[CrossRef](#)]
29. Nissen, M.H.; Claesson, M.H. Proteolytically modified human beta 2-microglobulin augments the specific cytotoxic activity in murine mixed lymphocyte culture. *J. Immunol.* **1987**, *139*, 1022–1029.
30. Nissen, M.H. Proteolytic modification of beta 2-microglobulin in human serum. *Dan. Med. Bull.* **1993**, *40*, 56–64.
31. Chou, P.Y.; Fasman, G.D. Prediction of the secondary structure of proteins from their amino acid sequence. *Adv. Enzymol. Relat. Areas Mol. Biol.* **1978**, *47*, 45–148. [[CrossRef](#)]
32. Kolaskar, A.S.; Tongaonkar, P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. *FEBS Lett.* **1990**, *276*, 172–174. [[CrossRef](#)]
33. Karplus, P.A.; Schulz, G.E. Prediction of chain flexibility in proteins—A tool for the selection of peptide antigens. *Naturwissenschaften* **1985**, *72*, 212–213. [[CrossRef](#)]
34. Parker, J.M.; Guo, D.; Hodges, R.S. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: Correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. *Biochemistry* **1986**, *25*, 5425–5432. [[CrossRef](#)]
35. Ravindranath, M.H.; Terasaki, P.I.; Pham, T.; Jucaud, V.; Kawakita, S. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E Abs that react with HLA-Ia (HLA-A/-B/-Cw) alleles. *Blood* **2013**, *121*, 2013–2028. [[CrossRef](#)]

36. Ravindranath, M.H.; Zhu, D.; Pham, T.; Jucaud, V.; Hopfield, J.; Kawakita, S.; Terasaki, P.I. Anti-HLA-E mAbs reacting with HLA-Ia and Ib alleles like IVIg as potential IVIg-immunomimetics: An evolving therapeutic concept. *Clin. Transpl.* **2013**, 293–305.
37. Ward, P.A.; Adams, J.; Faustman, D. *Monoclonal Antibody Production A Report of the*; Committee on Methods of Producing MAbs Institute for Laboratory Animal Research National Research Council National Academy Press: Washington, DC, USA, 1999; pp. 1–47.
38. Sasaki, T.; Ravindranath, M.H.; Terasaki, P.I.; Freitas, M.C.; Kawakita, S.; Jucaud, V. Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β 2m-free monomer. *Int. J. Cancer* **2014**, *134*, 1558–1570. [[CrossRef](#)] [[PubMed](#)]
39. Parham, P.; Barnstable, C.J.; Bodmer, W.F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. *J. Immunol.* **1979**, *123*, 342–349. [[PubMed](#)]
40. Smith, K.D.; Mace, B.E.; Valenzuela, A.; Vigna, J.L.; McCuthcheon, J.A.; Barbosa, J.A.; Huczko, E.; Engelhard, V.H.; Lutz, C.T. Probing HLA-B7 conformational shifts induced by peptide-binding groove mutations and bound peptide with anti-HLA mAbs. *J. Immunol.* **1996**, *157*, 2470–2478. [[PubMed](#)]
41. Vigna, J.L.; Smith, K.D.; Lutz, C.T. Invariant chain association with MHC class I: Preference for HLA class I/ β 2-m heterodimers, specificity, and influence of the MHC peptide-binding groove. *J. Immunol.* **1996**, *157*, 4503–4510.
42. Perosa, F.; Luccarelli, G.; Prete, M.; Favoino, E.; Ferrone, S.; Dammacco, F. Beta 2-m-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. *J. Immunol.* **2003**, *171*, 1918–1926. [[CrossRef](#)]
43. Carreno, B.M.; Hansen, T.H. Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. *Eur. J. Immunol.* **1994**, *24*, 1285–1292. [[CrossRef](#)]
44. Ravindranath, M.H.; El Hilali, F. Monospecific and Polyreactive MAbs against Human Leukocyte Antigen-E: Diagnostic and Therapeutic Relevance. In *Monoclonal Antibodies*; Resaei, N., Ed.; Intech Open: London, UK, 2021; 38p, ISBN 978-1-83968-370-1.
45. Jucaud, V.; Ravindranath, M.H.; Terasaki, P.I. Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Abs: Problems and Solutions. *Transplantation* **2017**, *101*, 764–777. [[CrossRef](#)] [[PubMed](#)]
46. Ravindranath, M.H.; Jucaud, V. Conformational variants of HLA-I antigens on Luminex Single Antigen Beads for monitoring Abs. *Transplantation* **2017**, *101*, e153–e154. [[CrossRef](#)] [[PubMed](#)]
47. Ravindranath, M.H.; Jucaud, V.; Ferrone, S. Monitoring native HLA-I trimer specific Abs in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. *J. Immunol. Methods* **2017**, *450*, 73–80, Erratum in **2018**, *460*, 125. [[CrossRef](#)] [[PubMed](#)]
48. Ravindranath, M.H. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a MAbs (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B-cells and Proliferation of CD4+ T-cells While Upregulating Tregs. *J. Immunol. Res.* **2017**, *2017*, 3475926. [[CrossRef](#)] [[PubMed](#)]
49. Jordan, S.C.; Quartel, A.W.; Czer, L.S.; Admon, D.; Chen, G.E.; Fishbein, M.C.; Schwieger, J.; Steiner, R.W.; Davis, C.; Tyan, D.B. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. *Transplantation* **1998**, *66*, 800–805. [[CrossRef](#)]
50. Jordan, S.C.; Vo, A.; Bunnapradist, S.; Toyoda, M.; Peng, A.; Puliyanda, D.; Kamil, E.; Tyan, D. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. *Transplantation* **2003**, *76*, 631–636. [[CrossRef](#)]
51. Perez, E.E.; Orange, J.S.; Bonilla, F.; Chinen, J.; Chinn, I.K.; Dorsey, M.; El-Gamal, Y.; Harville, T.O.; Hossny, E.; Mazer, B.; et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J. Allergy Clin. Immunol.* **2017**, *139*, S1–S46. [[CrossRef](#)]
52. Jordan, S.C.; Toyoda, M.; Vo, A.A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. *Transplantation* **2009**, *88*, 1–6. [[CrossRef](#)]
53. Zachary, A.A.; Montgomery, R.A.; Ratner, L.E.; Samaniego-Picota, M.; Haas, M.; Kopchaliiska, D.; Leffell, M.S. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. *Transplantation* **2003**, *76*, 1519–1525. [[CrossRef](#)]
54. Nair, V.; Sawinski, D.; Akalin, E.; Friedlander, R.; Ebcioğlu, Z.; Sehgal, V.; Dinavahi, R.; Khaim, R.; Ames, S.; Lerner, S.; et al. Effect of high-dose intravenous immunoglobulin on anti-HLA Abs in sensitized kidney transplant candidates. *Clin. Transplant.* **2012**, *26*, E261–E268. [[CrossRef](#)]
55. Alachkar, N.; Lonze, B.E.; Zachary, A.A.; Holechek, M.J.; Schillinger, K.; Cameron, A.M.; Desai, N.M.; Dagher, N.N.; Segev, D.L.; Montgomery, R.A.; et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen Abs in highly sensitized patients. *Transplantation* **2012**, *94*, 165–171. [[CrossRef](#)]
56. Marfo, K.; Ling, M.; Bao, Y.; Calder, B.; Ye, B.; Hayde, N.; Greenstein, S.; Chapochnik-Friedman, J.; Glicklich, D.; De Boccardo, G.; et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. *Transplantation* **2012**, *94*, 345–351. [[CrossRef](#)]
57. ELHilali, F.; Jucaud, V.; ELHilali, H.; Bhuiyan, M.H.; Mancuso, A.; LiuSullivan, N.; Elidrissi, A.; Mazouz, H. Characterization of the Anti-HLA Class I and II IgG Abs in Moroccan IVIg Using Regular Beads and Ibeads in Luminex Multiplex Single Antigen Immunoassay. *Int. J. Immunol.* **2017**, *5*, 53–65. [[CrossRef](#)]
58. Ravindranath, M.H.; Terasaki, P.I.; Pham, T.; Jucaud, V.; Kawakita, S. Suppression of blastogenesis and proliferation of activated CD4(+) T-cells: Intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E mAbs mimicking HLA-I reactivity of IVIg. *Clin. Exp. Immunol.* **2014**, *178*, 154–177. [[CrossRef](#)]

59. Kaveri, S.; Vassilev, T.; Hurez, V.; Lengagne, R.; Lefranc, C.; Cot, S.; Pouletty, P.; Glotz, D.; Kazatchkine, M.D. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. *J. Clin. Investig.* **1996**, *97*, 865–869. [[CrossRef](#)] [[PubMed](#)]
60. Klaesson, S.; Ringdén, O.; Markling, L.; Remberger, M.; Lundkvist, I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. *Scand. J. Immunol.* **1993**, *38*, 477–484. [[CrossRef](#)] [[PubMed](#)]
61. Miyagi, F.; Horiuchi, H.; Nagata, I.S.; Kitahara, S.; Kiyoki, M.; Komoriya, K.; Yuki, N. Fc portion of intravenous immunoglobulins suppresses the induction of experimental allergic neuritis. *J. Neuroimmunol.* **1997**, *78*, 127–131. [[CrossRef](#)]
62. Sali, A.D.; Karakasiliotis, I.; Evangelidou, M.; Avrameas, S.; Lymberi, P. Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin. *Clin. Transl. Immunol.* **2015**, *4*, e42. [[CrossRef](#)] [[PubMed](#)]
63. van Schaik, I.N.; Lundkvist, I.; Vermeulen, M.; Brand, A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. *J. Clin. Immunol.* **1992**, *12*, 325–334. [[CrossRef](#)]
64. Sbrana, S.; Ruocco, L.; Vanacore, R.; Azzarà, A.; Ambrogi, F. In vitro effects of an immunoglobulin preparation for intravenous use (IVIg) on T-cells activation. *Allerg. Immunol.* **1993**, *25*, 35–37.
65. Hurez, V.; Kaveri, S.V.; Mouhoub, A.; Dietrich, G.; Mani, J.C.; Klatzmann, D.; Kazatchkine, M.D. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). *Ther. Immunol.* **1994**, *1*, 269–277. [[PubMed](#)]
66. Amran, D.; Renz, H.; Lack, G.; Bradley, K.; Gelfand, E.W. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. *Clin. Immunol. Immunopathol.* **1994**, *73*, 180–186. [[CrossRef](#)]
67. Andersson, J.; Skansén-Saphir, U.; Sparrelid, E.; Andersson, U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. *Clin. Exp. Immunol.* **1996**, *104* (Suppl. 1), 10–20. [[CrossRef](#)]
68. Prasad, N.K.; Papoff, G.; Zeuner, A.; Bonnin, E.; Kazatchkine, M.D.; Ruberti, G.; Kaveri, S.V. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. *J. Immunol.* **1998**, *161*, 3781–3790. [[PubMed](#)]
69. Aktas, O.; Waiczies, S.; Grieger, U.; Wendling, U.; Zschenderlein, R.; Zipp, F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T-cells without inducing apoptosis. *J. Neuroimmunol.* **2001**, *114*, 160–167. [[CrossRef](#)]
70. MacMillan, H.F.; Lee, T.; Issekutz, A.C. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. *Clin. Immunol.* **2009**, *132*, 222–233. [[CrossRef](#)] [[PubMed](#)]
71. Aubin, E.; Lemieux, R.; Bazin, R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. *Blood* **2010**, *115*, 1727–1734. [[CrossRef](#)] [[PubMed](#)]
72. Tawfik, D.S.; Cowan, K.R.; Walsh, A.M.; Hamilton, W.S.; Goldman, F.D. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production. *Pediatr. Allergy Immunol.* **2012**, *23*, 88–95. [[CrossRef](#)]
73. Koffman, B.M.; Dalakas, M.C. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. *Muscle Nerve* **1997**, *20*, 1102–1107. [[CrossRef](#)]
74. Rodriguez, M.A.; De Sanctis, J.B.; Blasini, A.; Leon-Ponte, M.; Abadi, I. Human IFN-gamma up-regulates IL-2 receptors in mitogen-activated T lymphocytes. *Immunology* **1990**, *69*, 554–557.
75. Santos, S.G.; Antoniou, A.N.; Sampaio, P.; Powis, S.J.; Arosa, F.A. Lack of tyrosine 320 impairs spontaneous endocytosis and enhances release of HLA-B27 molecules. *J. Immunol.* **2006**, *176*, 2942–2949. [[CrossRef](#)] [[PubMed](#)]
76. Guild, B.C.; Strominger, J.L. Human and murine class I MHC antigens share conserved serine 335, the site of HLA phosphorylation in vivo. *J. Biol. Chem.* **1984**, *259*, 9235–9240. [[CrossRef](#)]
77. Mustelin, T.; Vang, T.; Bottini, T.N. Protein tyrosine phosphatases and the immune response. *Nat. Rev. Immunol.* **2005**, *5*, 43–57. [[CrossRef](#)] [[PubMed](#)]
78. Buckley, R.H.; Schiff, R.I. The use of intravenous immune globulin in immuno-deficiency diseases. *N. Engl. J. Med.* **1991**, *325*, 110–117. [[CrossRef](#)] [[PubMed](#)]
79. Kaveri, S.V.; Dietrich, G.; Hurez, V.; Kazatchkine, M.D. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. *Clin. Exp. Immunol.* **1991**, *86*, 192–198. [[CrossRef](#)]
80. McIntyre, J.A.; Higgins, N.; Britton, R.; Faucett, S.; Johnson, S.; Beckman, D.; Hormuth, D.; Fehrenbacher, J.; Halbrook, H. Utilization of intravenous immunoglobulin to ameliorate all-Abs in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. *Transplantation* **1996**, *62*, 691–693. [[CrossRef](#)]
81. Ippoliti, F.; De Santis, W.; Volterrani, A.; Canitano, N.; Frattolillo, D.; Lucarelli, S.; Frediani, S.; Frediani, T. Psychological stress affects response to sublingual immunotherapy in asthmatic children allergic to house dust mite. *Pediatr. Allergy Immunol.* **2006**, *17*, 337–345. [[CrossRef](#)]
82. Glotz, D.; Antoine, C.; Julia, P.; Suberbielle-Boissel, C.; Boudjeltia, S.; Fraoui, R.; Hacen, C.; Duboust, A.; Bariety, J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). *Am. J. Transplant.* **2002**, *2*, 758–760. [[CrossRef](#)]
83. Sethi, S.; Choi, J.; Toyoda, M.; Vo, A.; Peng, A.; Jordan, S.C. Desensitization: Overcoming the Immunologic Barriers to Transplantation. *J. Immunol. Res.* **2017**, *2017*, 6804678. [[CrossRef](#)]
84. Jordan, S.C.; Tyan, D.; Stablein, D.; McIntosh, M.; Rose, S.; Vo, A.; Toyoda, M.; Davis, C.; Shapiro, R.; Adey, D.; et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. *J. Am. Soc. Nephrol.* **2004**, *15*, 3256–3262. [[CrossRef](#)]

85. Ross, C.N.; Gaskin, G.I.; Gregor-Macgregor, S.U.; Patel, A.A.; Davey, N.J.; Lechler, R.I.; Williams, G.O.; Rees, A.J.; Pusey, C.D. Renal transplantation following immunoadsorption in highly sensitized recipients. *Transplantation* **1993**, *5*, 785–789. [[CrossRef](#)]
86. Larabi, A.; Backman, U.; Wikstrom, B.; Sjoberg, O.; Tufveson, G. Pretransplantation plasmapheresis in HLA-sensitized patients: Five years experience. *Transplant. Proc.* **1995**, *27*, 3448.
87. Stegall, M.D.; Gloor, J.; Winters, J.L.; Moore, S.B.; Degoey, S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. *Am. J. Transplant.* **2006**, *6*, 346–351. [[CrossRef](#)]
88. Onrust, S.V.; Lamb, H.M.; Balfour, J.A. Rituximab. *Drugs* **1999**, *58*, 79–88. [[CrossRef](#)] [[PubMed](#)]
89. Vo, A.A.; Lukovsky, M.; Toyoda, M.; Wang, J.; Reinsmoen, N.L.; Lai, C.H.; Peng, A.; Villicana, R.; Jordan, S.C. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N. Engl. J. Med.* **2008**, *359*, 242–251. [[CrossRef](#)]
90. Vo, A.A.; Peng, A.; Toyoda, M.; Kahwaji, J.; Cao, K.; Lai, C.H.; Reinsmoen, N.L.; Villicana, R.; Jordan, S.C. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. *Transplantation* **2010**, *89*, 1095–1102. [[CrossRef](#)]
91. Vo, A.A.; Choi, J.; Cisneros, K.; Reinsmoen, N.; Haas, M.; Ge, S.; Toyoda, M.; Kahwaji, J.; Peng, A.; Villicana, R.; et al. Benefits of rituximab combine with intravenous immunoglobulin for desensitization of kidney transplant recipients. *Transplantation* **2014**, *98*, 312–319. [[CrossRef](#)]
92. Zhu, D.; Ravindranath, M.H.; Terasaki, P.I.; Miyazaki, T.; Pham, T.; Jucaud, V. Suppression of allo-human leucocyte antigen (HLA) A2 secreted by B memory cells in vitro: Intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. *Clin. Exp. Immunol.* **2014**, *177*, 464–477. [[CrossRef](#)]
93. Baecher-Allan, C.; Brown, J.A.; Freeman, G.J.; Hafler, D.A. CD4+CD25+ high regulatory cells in human peripheral blood. *J. Immunol.* **2001**, *167*, 1245–1253. [[CrossRef](#)] [[PubMed](#)]
94. Ng, W.F.; Duggan, P.J.; Ponchel, F.; Matarese, G.; Lombardi, G.; Edwards, A.D.; Isaacs, J.D.; Lechler, R.I. Human CD4+CD25+ cells: A naturally occurring population of regulatory T-cells. *Blood* **2001**, *98*, 2736–2744. [[CrossRef](#)]
95. Li, Y.; Koshihara, T.; Yoshizawa, A.; Yonekawa, Y.; Masuda, K.; Ito, A.; Ueda, M.; Mori, T.; Kawamoto, H.; Tanaka, Y.; et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. *Am. J. Transplant.* **2004**, *4*, 2118–2125. [[CrossRef](#)]
96. Pons, J.A.; Revilla-Nuin, B.; Baroja-Mazo, A.; Ramirez, P.; Martínez-Alarcón, L.; Sánchez-Bueno, F.; Robles, R.; Rios, A.; Aparicio, P.; Parrilla, P. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. *Transplantation* **2008**, *86*, 1370–1378. [[CrossRef](#)]
97. Baroja-Mazo, A.; Revilla-Nuin, B.; Parrilla, P.; Martínez-Alarcón, L.; Ramirez, P.; Pons, J.A. Tolerance in liver transplantation: Biomarkers and clinical relevance. *World J. Gastroenterol.* **2016**, *22*, 7676–7691. [[CrossRef](#)] [[PubMed](#)]
98. Baroja-Mazo, A.; Revilla-Nuin, B.; de Bejar, Á.; Martínez-Alarcón, L.; Herrero, J.I.; El-Tayeb, A.; Müller, C.E.; Aparicio, P.; Pelegrín, P.; Pons, J.A. Extracellular adenosine reversibly inhibits the activation of human regulatory T-cells and negatively influences the achievement of the operational tolerance in liver transplantation. *Am. J. Transplant.* **2019**, *9*, 48–61. [[CrossRef](#)]
99. Jhun, J.; Lee, S.H.; Lee, S.K.; Kim, H.Y.; Jung, E.S.; Kim, D.G.; Choi, J.; Bae, S.H.; Yoon, S.K.; Chung, B.H.; et al. Serial monitoring of immune markers being represented regulatory T cell/T helper 17 cell ratio: Indicating tolerance for tapering immunosuppression after liver transplantation. *Front. Immunol.* **2018**, *9*, 352. [[CrossRef](#)] [[PubMed](#)]
100. Sablik, K.A.; Jordanova, E.S.; Pocorni, N.; Clahsen-van Groningen, M.C.; Betjes, M.G.H. Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection. *Front. Immunol.* **2019**, *10*, 3106. [[CrossRef](#)] [[PubMed](#)]
101. Dai, H.; Zheng, Y.; Thomson, A.W.; Rogers, N.M. Transplant Tolerance Induction: Insights from the Liver. *Front. Immunol.* **2020**, *11*, 1044. [[CrossRef](#)] [[PubMed](#)]
102. Hara, M.; Kingsley, C.I.; Niimi, M.; Read, S.; Turvey, S.E.; Bushell, A.R.; Morris, P.J.; Powrie, F.; Wood, K.J. IL-10 is required for regulatory T-cells to mediate tolerance to alloantigens in vivo. *J. Immunol.* **2001**, *166*, 3789–3796. [[CrossRef](#)] [[PubMed](#)]
103. Levings, M.; Sangregorio, R.; Roncarolo, M.G. Human CD25+CD4+ T regulatory cells suppress naive and memory T-cell proliferation and can be expanded in vitro without loss of function. *J. Exp. Med.* **2001**, *193*, 1295–1301. [[CrossRef](#)]
104. van Maurik, K.; Wood, J.; Jones, N. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T-cell-mediated graft rejection: Implications for anti-CD154 immunotherapy. *J. Immunol.* **2002**, *169*, 5401–5404. [[CrossRef](#)]
105. Lin, C.-Y.; Graca, L.; Cobbold, S.P.; Waldmann, H. Dominant transplantation tolerance impairs CD8+ T-cell function but not expansion. *Nat. Immunol.* **2002**, *3*, 1208–1213. [[CrossRef](#)]
106. Graca, L.; Cobbold, S.P.; Waldmann, H. Identification of regulatory T-cells in tolerated allografts. *J. Exp. Med.* **2002**, *195*, 1641–1646. [[CrossRef](#)] [[PubMed](#)]
107. Cobbold, S.P.; Waldmann, H. Regulatory cells and transplantation tolerance. *Cold Spring Harb. Perspect. Med.* **2013**, *3*, a015545. [[CrossRef](#)] [[PubMed](#)]
108. Kikuchi, J.; Hashizume, M.; Kaneko, Y.; Yoshimoto, K.; Nishina, N.; Takeuchi, T. Peripheral blood CD4(+) CD25(+) CD127 (low) regulatory T-cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T-cells correlates with clinical response. *Arthritis Res. Ther.* **2015**, *17*, 1–10. [[CrossRef](#)] [[PubMed](#)]
109. Ephrem, A.; Chamat, S.; Miquel, C.; Fisson, S.; Mouthon, L.; Caligiuri, G.; Delignat, S.; Elluru, S.; Bayry, J.; Lacroix-Desmazes, S.; et al. Expansion of CD4+CD25+regulatory T-cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. *Blood* **2008**, *111*, 715–722. [[CrossRef](#)] [[PubMed](#)]

110. Filippone, E.J.; Das, B.; Norin, A.J.; Ravindranath, M.H. Optimizing the assessment of pathogenic anti-HLA antibodies. *Am. J. Transplant.* **2021**, *21*, 431–432. [[CrossRef](#)]
111. Arosa, F.A.; Esgalhado, A.J.; Padrão, C.A.; Cardoso, E.M. Divide, Conquer, and Sense: CD8+CD28- T-cells in Perspective. *Front. Immunol.* **2017**, *7*, 665. [[CrossRef](#)]
112. Arosa, F.A.; de Jesus, O.; Porto, G.; Carmo, A.M.; de Sousa, M. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. *J. Biol. Chem.* **1999**, *274*, 16917–16922. [[CrossRef](#)]
113. Allen, R.L.; Trowsdale, J. Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors. *Curr. Mol. Med.* **2004**, *4*, 59–65. [[CrossRef](#)]
114. Jones, D.C.; Kosmoliaptis, V.; Apps, R.; Lapaque, N.; Smith, I.; Kono, A.; Chang, C.; Boyle, L.H.; Taylor, C.J.; Trowsdale, J.; et al. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. *J. Immunol.* **2011**, *186*, 2990–2997. [[CrossRef](#)]
115. Tamir, I.; Cambier, J.C. Antigen receptor signaling: Integration of protein tyrosine kinase functions. *Oncogene* **1988**, *17*, 1353–1364. [[CrossRef](#)] [[PubMed](#)]
116. Angulo, R.; Fulcher, D.A. Measurement of Candida-specific blastogenesis: Comparison of carboxyfluorescein succinimidyl ester labelling of T-cells, thymidine incorporation, and CD69 expression. *Cytometry* **1998**, *34*, 143–151. [[CrossRef](#)]